THE HAGUE 9-10 MARCH 2016 Report and appendices. 91 ST SESSION OF THE EXECUTIVE COMMITTEE OF THE EuFMD COMMISSION

Transcription

1 THE HAGUE 9-10 MARCH 2016 Report and appendices 91 ST SESSION OF THE EXECUTIVE COMMITTEE OF THE EuFMD COMMISSION FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS EUROPEAN COMMISSION FOR THE CONTROL OF FOOT-AND-MOUTH DISEASE (EuFMD) Rome, 2016

2

3 Table of Contents CONCLUSIONS 3 Item 1: Adoption of Agenda 6 Item 2: Report of EuFMD activities since the 90 th Session 6 Item 3. Update and questions arising from the implementation of the workplan. 7 A: Training programmes 7 B: Emergency Preparedness 8 C: Progressive Control of FMD- in the neighbourhood and in support of global strategy 8 D: Prioritisation of applied research and surveillance 9 Item 3E: Small group discussions 9 Item 5: FMD situation Global and Regional 14 a) Report of the FAO World Reference Laboratory (WRL) for FMD, Pirbright 14 b) Report on the FMD situation in Turkey and neighbours: (WELNET report) 16 FMD situation in the Caucasus countries 18 c): Report on the situation in North Africa 19 d): World Reference Laboratory (WRL) contract 20 Item 6: Items proposed by Gf-TADs Partners 21 Item 7: Standing Technical Committee 25 Item 8: Administrative and financial 27 Item 9: Co-ordination, future meetings 28 Appendices Appendix 1: Agenda Appendix 2: Report on Activities of the Secretariat, K.Sumption Appendix 3: Training update, J.Maud Appendix 4: Emergency preparedness update, M.Masiulis Appendix 5: EuFMD activities in Near East, North Africa and under Pillar III, C.Bartels Appendix 6: Report of the FAO World Reference Laboratory, D.King Appendix 7: Report on the FMD situation in Turkey and neighbours, N.Bulut Appendix 8: FMD situation in the Caucasus countries, N.Lebedev Appendix 9: Report of FMD in North Africa, JL.Angot Appendix 10: GF-TADs partners, J.Lubroth Appendix 11: Standing Technical Committee report, E.Ryan 91st Executive Committee of the EuFMD, The Hague, 9-10 March

4

5 Findings and Conclusions of the 91 st Session of the Executive Committee The Executive Committee, after considering the documents and issues on the Agenda of the 91 st Session of the Executive Committee of the EuFMD, Acknowledges The support of the European Commission for the Phase III of the EuFMD/EC work programme and to emergency actions in the European neighbourhood, the continued support of the Member States for the Secretariat of the Commission, and the interest of international partners to work together under the Global Strategy for Foot and Mouth Disease (FMD) towards common objectives that will reduce the risk of new FMD epidemics. In relation to the general FMD risk situation 1. The recent jumps of infection from South Asia into the Middle-East, and the rapid spread between countries in the south-eastern European neighbourhood should be noted by the member states as a major cause for concern. 2. Laboratory and field studies on the level of protection provided by serotype A antigens in the EU bank and the new A G-VII vaccines are urgently required. The possibility to undertake such studies in the field in Iran or Turkey should be pursued vigorously. 3. The SAP Institute, Turkey, is to be commended for the very quick development of a homologous vaccine to the epidemic type A G-VII strain, and the GDFC for bringing forward the spring campaign to ensure early, national re-vaccination of the national herd, a very major logistical and practical achievement. 4. As the detection of the new strain and the initiation of vaccine development occurred before the international reporting of detection of the new strain, the Executive must remind its member states of the obligation to report epidemiologically significant events to the OIE and, in line with its mandate, also to the EuFMD. 5. The SAP Institute, as leader of the WELNET, together with the WRL and FGI-ARRIAH, had provided valuable information in English and Russian to the FMD laboratory network in the countries of West Eurasia and the Middle-East. 6. WELNET, working with WRL and FGI-ARRIAH, should urgently develop vaccine recommendations for West Eurasia for the upcoming Roadmap Meeting, and in future ensure it follows closely the situation in the Arabian Peninsula which now appears to be an entry point for infection to Turkey/Iran/TransCaucasus. 7. Surveillance to provide confidence in the absence of virus circulation in regions recently affected by FMD in North Africa is required. Support to the design and implementation could be provided under Component 2.3 of the EuFMD/REMESA workplan. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

6 Conclusions 1. Considering that human resources can be critically constrained during emergency responses, the EuFMD should develop and consult upon a set of Guidelines on human resource sharing, to ensure MS are aware of issues and their potential solutions, firstly targeting non-eu countries (i.e. western Balkans). 2. The area of decision-making upon the use of emergency vaccination in free countries remains a priority for member states. It was recommended that EuFMD proceed through a process involving 1) an expert consultation to prioritise issues, inform the objectives and design of a workshop, 2) a well-structured workshop involving multiple member states, based on the recommendations of the consultation, and 3) wide dissemination of the findings of the workshop to all Member States. 3. The practical management of emergency vaccination programmes requires to be tested in many countries and remains an important planning issue. It was recommended to investigate whether training in this field could be combined with neighbourhood/north African countries where such emergency campaigns have been recently conducted and which are interested to improve their emergency preparedness. 4. Regarding the development of diagnostic bank, the idea of focussing initial development to the FMD free, non-eu countries (i.e. western Balkans) was endorsed, with the lead taken under Component Regarding leveraging funds for improved international surveillance, it was recommended to proceed with caution and to report back to the next Session on the outcome of the pilot round of the FASTA process. 6. The need to increase the uptake and application of the PCP, at regional and national levels was recognised. The Committee gave general encouragement to exploration by the Secretariat of alternative routes to disseminate the PCP-FMD approach. The broadcasting of webinar series, the development of e-learning modules and courses, establishing a Knowledge Bank including Job Aids was supported as potential ways forward to effectively disseminate the PCP-FMD approach to large groups of stakeholders from both the public and private sector. 7. The EuFMD training programme was also recognised as making a contribution to continuing professional development (CPD) of national public service officials in Europe. The requirement for CPD of veterinarians in the neighbourhood countries is limited, and EuFMD training contents could be examples that could assist competent authorities to roll out CPD to their officers using the cascade training model. 8. Greater attention must be given to obtaining up to date information on virus circulation in South Asia, especially India, and the identification of effective vaccines. The real-time training programme in Nepal has provided a useful opportunity to ensure samples are collected and submitted for typing, but a more strategic approach to ensure active South Asian participation in FMD surveillance is required. The Regional Support Unit (RSU) to SAARC countries could play an important role, and South Asia should be prioritised for more attention under the Pillar III networking and training action plan. 9. Regarding co-ordination of FMD prevention and control in the Trans-Caucasus countries, the pilot programme proposal from the Russian Federation on six countries involving into the entire animal population vaccination was appreciated. Recognising the investment and commitment of each state, and the need for clarity and commitment on future national surveillance objectives and progression in the PCP, a meeting involving the representatives of Georgia, Armenia, Azerbaijan, Turkey, Iran and the Russian Federation should be convened during the OIE General Session held later on this year in May The EuFMD could provide the Secretariat for the meeting, and would co-ordinate this with OIE, FAO and EC. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

7 10. The following requests from the GF-TADS Working Group for the inclusion in the work-plans under Pillar III were endorsed: a. PCP Training for FAO and OIE staff to improve the awareness, and increase the appropriate application of the PCP-FMD tool, with the ultimate goal to have all regional / sub-regional officers being able to provide guidance to countries and to better follow-up their respective regional roadmap. b. Revision of the PCP-FMD guidelines and associated questionnaires, by building on the experiences gained and to include Component 2 of the FMD Global Strategy (Strengthening Veterinary Services). c. Guiding materials for FMD control plans required such as templates for control plans - to support countries willing to progress to PCP Stages 1, 2 and 3 and to advance in their PCP stage, and including the post-vaccination monitoring (PVM) and the socio-economic guidelines. d. Assistance in the processes of acceptance of Regional Leading Laboratories in particular in North Africa, Eastern African and Western Africa. e. Relating to REMESA, the OIE proposal that EuFMD be represented on the Steering Committee of the regional vaccine bank for North Africa, and also provide an expert to the workshop on development of a regional vaccination strategy, were supported. 11. The five proposed priorities for support under the Fund for Applied Research were endorsed, for inclusion in the calls for research to be conducted in the first 24 months of Phase IV. 12. Regarding the development of diagnostic bank, the idea of focussing initial development to the FMD free, non-eu countries (i.e. western Balkans) was endorsed, with the lead taken under Component The Secretariat was authorised to continue to support on an interim basis the initial activities of the Phase IV EC programmes from MTF/INT/011/MUL, on the understanding that these costs could be charged to the EC funds, with backdating until 1 st October The 92 nd Session of the Executive dates are proposed as September 2016, in Paris, France. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

8 Report of the 91 st Session of the EuFMD Executive Committee The Session was opened by Dr Christianne Bruschke, Vice Chairperson of the Executive Committee and Chief Veterinary Officer of the Netherlands. She welcomed all the members, observers and technical experts to The Hague. The Netherlands was a founding member of the EuFMD Commission in 1954 and she emphasised the importance of the Commission s work for its member states and to reduce the risk of FMD incursions from the neighbourhood and the continued concerns over entry of infection from any parts of the world where infection is circulating. The Netherlands had provided several Officers of the Commission over the past 60 years and she was delighted to have the honour to continue this important role. The Session was attended by eight of the nine elected officers and members, with apologies received from Dr Dejan Bujarski, Serbia. Officers of the Commission present were: Dr Jean-Luc Angot (JLA, France, President) Dr Christianne Bruschke (CB, The Netherlands, Vice President) and Dr Ulrich Herzog (UH, Austria, Vice-President). Members of the Executive Committee present were Dr Spiros Doudounakis (SD, Greece), Dr Martin Blake (MB, Ireland), Dr Gediminas Pridotkas (GP, Lithuania), and Dr Lajos Bognar (LB, Hungary). Dr Irfan Erol (IE, Turkey) was represented by Dr Ozhan Turkyilmaz, GDFC (OT, Turkey). Observers from the international organizations were Dr Alf-Eckbert Füssel (AEF, Head of Sector, DG-SANTE), Dr Juan Lubroth, CVO-FAO (FAO), and Drs Jean-Philippe Dop (OIE) and Alessandro Ripani representing the OIE. Dr Don King represented the WRL-FMD at The Pirbright Institute (TPI), and Dr Naci Bulut the SAP Institute, Turkey. Dr Evgeny Nepoklonov, CVO, and Dr Lebedev, Rosselskhoznador, Russian Federation, attended as Observers by agreement with the Chairperson of the Commission. The Secretariat for the 91 st Session comprised Dr Keith Sumption (KS, EuFMD Executive Secretary), Dr Jenny Maud (JM) (Training Programmes Officer), Dr Marius Masiulis (MM, Contingency Planning Officer), and Dr Chris Bartels (CB, Component 3.2 Manager, PCP). Item 1: Adoption of Agenda (Appendix 1) The Agenda was adopted after agreement on an additional item concerning FMD control in the regions of the Russian Federation bordering to the Trans-Caucasus. The Secretariat provided a bound set of documents that included Final Workplan for EuFMD activities ; Report on Activities since the 90 th Session, and the Administrative and Financial Report; Report of the 90th Session; Proposals for changes to the workplan of Component 2.1 (Turkey and Georgia, West Eurasia). Item 2: Report of EuFMD activities since the 90 th Session The report of EuFMD activities since the 90 th Executive Committee meeting was presented by Dr Keith Sumption (Appendix 2). Dr Sumption discussed EuFMD activities in response to the major FMD risk events of the period, namely the epidemic of FMD serotype A (G-VII genotype) in the Arabian peninsula, Turkey, Armenia and Iran and the spread of the North African serotype O epidemic into Morocco in October st Executive Committee of the EuFMD, The Hague, 9-10 March

9 Phase III of the EuFMD work programme was operationally closed at the end of September The signing of the Phase IV agreement with the EC has been delayed. An informal agreement has been reached with DG-SANTE to backdate the start date of the agreement to October On the date of the Executive meeting the agreement had not been signed, although this was anticipated to occur shortly. The delay to the signature of the agreement had posed challenges to the Executive, with interim funding provided by the MS trust fund. The Executive had been unable to issue any long contracts to personnel or partners, and Dr Sumption thanked those concerned for their patience and loyalty. Given funding constraints priority has been given to: Thrace (component 1.3) given LSD epidemic situation, and from November, the new epidemic of type A in Turkey; Online and remote support: development of webinars to support components 1.2, 1.3 and 1.4 with involving component 2.1 activities and online training courses; Training needs assessments; Support to regional networks (virtual support), to FAO/OIE at the Middle East roadmap meeting, consultative meetings in the Middle East and with the I.R of Iran. The Administrative and Financial Report was provided Dr Sumption at this point, but reported under Item 8. Item 3. Update and questions arising from the implementation of the workplan. Short presentations were provided that gave the background to the issues subsequently discussed in detail by the working groups in the afternoon. After reporting back and discussion in the plenary, the conclusions reached are reported at the end of Item 3. a) Training programmes Dr Jenny Maud presented an update (Appendix 3) on the training programme (components 1.1, 2.4 and 3.4). In improving the infrastructure for online training, EuFMD administrative staff had been trained to assist with management of e-learning courses and an update to the appearance and functionality of the EuFMD e-learning platform is underway in partnership with the Royal Veterinary College. Development of the online knowledge bank had been slightly delayed due to EC funding delays. Dr Maud reported on the training needs assessment carried out for EuFMD Member States under component 1.1. This had now been nearly completed with 35 responses received, and the MS had indicated their selection of training courses through the training credits (TC) system. As a result, the selection of courses by MS was now clear and almost all of the TC available for the two years of the programme had been assigned. The results of the training needs assessment highlighted areas which MS identified as lower competencies, particularly decision making and preparedness for implementation of vaccination programmes. Development of supporting materials to enable MS to provide their own in country training courses is underway, with pilot projects occurring with Italy and Germany. Germany has funded 22 places on a bespoke Real Time Training course. Training needs assessment was currently underway in Pillar II countries, following a similar format to that carried out for 1.1. E-learning on the PCP-FMD is in the final stages of completion. A short Term Professional (STP) (Obakeng Kemolathle, Botswana) to assist with activities under Pillar III, including training, has been selected and activities under this component were expected to be greatly assisted by this. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

10 b) Emergency Preparedness Dr Marius Masiulis presented an update (Appendix 4) on the workplan components that involve emergency preparedness of the member states (1.2), in Thrace (1.3) and the Western Balkan countries (1.4). Of note: At the end of November 2015, the EuFMD launched a Practical FMD management programme for the MS participating in components 1.2, 1.3, 1.4 and neighbourhood countries (Component 2.1), in English and in Russian. The programme consists in two parts introductory and main. The main part is be divided into five modules and each module is made from several (up to three) webinars. Participants receive a certificate of attendance once they complete a module, pass a short quiz with a satisfactory mark and participate in webinar series discussion forum. Relating to the Contingency Planning network, a database of the national experts has been developed, to assist in development of specific parts of Operational manual, (as part of the Contingency Plan). The database will assist identifying persons to share experience and request participation as tutors, in exercises and webinars, discussion forums and in case of animal disease outbreak. For the Modelling network, two webinars have been held, and a subgroup of modeling network has submitted a proposal to Horizon 2020 which, if funded, would involve the development of a pan- European disease spread model, as recommended by the General Session. A new database and display system for management of activities for early warning surveillance in the Thrace region of Bulgaria/Greece/Turkey has been developed and tested. The new Database is based on Google Fusion Tables and was launched on 1 January 2016 in parallel with the existing SharePoint. During the 1 st cycle, the new software will be tested and possible issues will be improved. Depending on the outcome, the EuFMD could shift to the new Google Fusion database completely from the beginning of the 2 nd cycle A Practical training for wildlife surveillance for Foot-and-Mouth Disease workshop was conducted in Bulgaria under component 1.3 and 1.4, with 22 contingency planners/ wildlife specialist in February Plans were also advanced for the upcoming Laboratory Surveillance Exercise for Balkan region with expected participation of 11 countries. c) Progressive Control of FMD- in the neighbourhood and in support of global strategy Dr Chris Bartels gave a short presentation (Appendix 5) on EuFMD s activities in Near East, North Africa (component 2.1) and under Pillar III (except for component 3.3). Activities in Palestine need to be followed up while activities in Lebanon and Jordan are currently being planned. A constraint under Pillars II and III is the limited number of experts capable of managing the in country work that involves development of national FMD control strategies. Part of the short term solution involves training of the STP officers from MS and from North Africa. With regard to component 3.1, activities depend on requests from the FAO/OIE FMD working group. No such requests have been received. The EuFMD expects that in the next period, the working group will come forward with request for support on the Annual Global FMD report (activity 3.1.2) on training of FMD experts (Activity 3.1.3) and potentially in-country mission up request (activity 3.1.3). For Component 3.2, EuFMD has been providing substantial input for the socio-economic guidelines on FMD control and participation in the Regional Roadmap meeting for North Africa and the Near East in Doha, Qatar in December Currently, the EuFMD is supporting the revision of the PCP-FMD guidelines and developing materials for PCP-FMD training of FAO and OIE regional staff. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

11 Under component 3.4, there is high demand for training from across the globe while there are limited resources (funds, capacity, and time) under this Component. Dr Bartels put forward a number of points for discussion on how to transfer knowledge and skills to national practitioners, which were discussed in the group discussions. d) Prioritization of applied research and surveillance Dr Eoin Ryan (Chair, Standing Technical Committee (STC)) summarised conclusions from the recent STC meeting. The EC Horizon 2020 research funding program does not include a specific call for funding proposals related to FMD. EuFMD s Fund for Applied Research (FAR) is therefore the only FMD specific research fund at European Level. The STAR-IDAZ consortium is a global grouping seeking to identify research priorities for international animal disease issues, including FMD, and may present an opportunity for leveraging prioritisation of the research priorities identified by EuFMD. The FAR itself traditionally supports the Global Foot and Mouth Disease Research Association (GFRA) to produce a state of FMD research report every two years, and Dr Ryan queried whether there was need to commission a specific report on European research priorities in order to better identify these. Dr Ryan reported that the STC identified the following research priorities at their recent meeting: Tools to assist modelling FMD spread with respect to national data compatibility issues; Practical application of the latest bio secure FMD sample transport research; Application of FMD impact calculators to contingency planning; Requirements for approving FMD marker vaccines within the EU; Tools to manage the spread of FMD in wildlife. Dr Ryan updated the Executive on the FMD Amplified Surveillance Technology Transfer and Training Awards (FASTA) concept, recently endorsed by the STC. The FASTA concept functions as a catalyst to develop partnerships to improve surveillance activities, leveraging existing investments to generate additional outputs. Some initial success in achieving such partnerships has been achieved between Nigeria and Belgium. He also reported that further discussion had been held with Dr Herzog (UH, Austria) on the concept of a diagnostic bank. An initial pilot bank was proposed which include the diagnostic reagents required for the acute phase of an outbreak, focussed on the Balkans region. This matter was further discussed in the small group sessions. e) Small group discussions The Executive were divided into two groups for the discussion session. Group One Alf Füssel Ulrich Herzog Spiros Doudounakis Martin Blake Alessandro Ripani Lajos Bognar Jenny Maud Marius Masiulis Eoin Ryan (part) Keith Sumption (part) Group Two Jean-Luc Angot Christianne Bruschke Jean-Phillippe Dop Juan Lubroth A.Naci Bulut Gediminas Pridotkas Ozhan Turkyilmaz Chris Bartels Eoin Ryan (part) Keith Sumption (part) 91st Executive Committee of the EuFMD, The Hague, 9-10 March

12 Item 4: Feedback from Group discussion Discussion Group 1 Emergency Preparedness: Component 1.2, the issue of critical human resources Questions discussed by the group: 1. Should we have as a priority the sharing of human resources? Is it important for all MS or only for a specific region? 2. Do we need to develop template for bilateral agreement and present for MS CVO for further discussion? The members of Executive Committee agreed on the importance of the human resource sharing and concluded, that: 1. For the EU countries, the CVET (Community Veterinary Emergency Team) already exists to help Member States veterinary authorities, and should provide a system for assistance. This may function as means to find critically constrained human resources that can be useful to other Member States; 2. The sharing of human resources can only be done only on voluntary basis; 3. Language barriers will be one of the most important problems, as few MS share common languages with more than one other country in Europe. 4. Reducing the bureaucratic burden was necessary to make the sharing of expertise more attractive and feasible. Common issues include maintenance allowances, contracts, insurance, rates, accommodation, and a template or guidance may assist MS to develop a streamlined process; 5. The guidelines would be useful for all MS but target could be firstly non-eu neighbourhood Balkan region. Conclusion 15. The EuFMD should prepare and distribute for the further discussions Guidelines on human resource sharing that ensure MS are aware of issues and their potential solutions, firstly targeting non-eu countries (i.e. western Balkans). Priorities for support to MS on vaccination issues Relating to lower competencies in preparedness for FMD vaccination identified by the training needs assessment, the questions below were discussed: Where are the biggest gaps in our support to MS and how could they be addressed? (Training, research priority, vaccination network). What is the relative importance of the following topics for more attention? 1. Decision making on whether to vaccinate, implications of OIE code change, exit strategies to vaccination. 2. Practical planning on how to implement emergency vaccination. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

13 The discussion group agreed that further support on decision making regarding vaccination should be prioritized. This should include consideration of: Trade implications of vaccination and exit strategy following vaccination. Dr Füssel raised the particular issue of trade in live vaccinated animals between EU Member States. It is likely that there are wide differences in the impact of FMD vaccination according to trading patterns of EuFMD MS. Support to strategic decision making on vaccination, and communication to decision makers (government ministers). Could a tool be developed to assist decision making? Need to consider the changed landscape since 2001, including public opinion changes, and technological changes including e.g. rendering. Need to look broadly at decision making; Dr Herzog commented on the value of including a broader view of veterinary ethics and wide stakeholder consultation in the decision making process. Recommendation 1. To prioritise support to the area of decision-making on use of vaccination, through a process involving 1) an expert consultation to inform the design of a workshop, 2) a well-structured workshop involving multiple member states, based on the recommendations of the consultation, and 3) wide dissemination of the findings of the workshop to all Member States. 2. The practical management of emergency vaccination programmes remain important and it was recommended to investigate whether training in this field could be combined with neighbourhood/north African countries where such emergency campaigns have been recently conducted and which are interested to improve their emergency preparedness. Implementing an EuFMD diagnostic bank The group discussed the establishment of a diagnostic bank for reagents needed for testing samples from suspected clinical FMD cases (PCR, antigen detection ELISA, antibody detection ELISA, LFDs) during the initial phase of an outbreak (i.e. not the post-outbreak serosurveillance phase). The idea of focussing initial development to the FMD free, non-eu countries (i.e. Western Balkans) was endorsed by the group. They considered that such a bank should be based in an FMD reference laboratory (e.g. IZSLER) with a commercial courier company contracted to transport reagents within 48 hours of a request being made. A least cost method should be explored by the Secretariat. If kits are purchased, a system for use of kits approaching their use-by dates should be agreed, which may involve donation to countries under other parts of the EuFMD programme. The bank should be linked to existing laboratory networks and contingency planning networks, and beneficiary NRLs should have had appropriate training, coordinated with the EURL/WRL. Although the regional focus of the bank could be the Balkan non-eu members, the existence of the bank could assist if crisis occurs in an EU member if the bank is not restricted solely to these countries. Eoin Ryan (STC) was invited by Don King (WRL) to give a talk on this subject at the EURL FMD meeting in May st Executive Committee of the EuFMD, The Hague, 9-10 March

14 Discussion group 2 Prioritisation of applied research and surveillance: 1. Coordination: The group discussed the issue of the extent to which the FAR should coordinate with other research funders and consortia. The consensus was that the limited funding available for FMD research affects national FMD laboratory function and capacity and restricts the development of better technical options in disease control and risk management. Advocacy was needed to argue the case for more FMD-specific research with funding bodies such as DG-Research. More socio-economic research on the impact of FMD would be useful both as an end in itself but also as it would inform such advocacy. Coordination of FAR priorities with other research consortia such as STAR-IDAZ could be positive, particularly in order to avoid unnecessary duplication of research efforts. However the group noted the risk of the EuFMD losing control of its own research agenda if there was excessive coordination; there was a value in staying in control of FAR fund priorities. Within the context of limited funding available for FMD research, the option of exploring the IAEA CRP funding mechanism was recommended. 2. Leverage: The group discussed the suggestion that the EuFMD could play a role in leveraging funding towards activities that will contribute to achieving the agreed outcomes of the Strategic Plan. This has developed since some funding agencies or sources have shown an interest to support areas of FMD surveillance and training, particularly in Middle-east and Africa, and for which the Phase IV funding is very limited. As a result of such external funding interest the Secretariat developed the EuFMD FASTA mechanism, with a particular emphasis on disease surveillance and virus isolate characterisation, involving a competitive process with objectives to identify quality proposals that address gaps in surveillance and which external agencies may be willing to support. The consensus was that while the group supported the outputs which this is intended to serve (improved disease intelligence to inform European risk management), the group advised caution with regard to the modalities proposed. There is a risk that this approach is opportunistic rather than strategic, and care should be taken to ensure any EuFMD activities of this sort are strategically aligned. The issue of data ownership in relation to funding bodies was flagged as an important point. There may be reputational risks to EuFMD arising from a perception of having a close relationship with private companies or certain countries, or from being perceived to be acting as a contractor for others, which may create difficulties for the EuFMD core work. The possibility to obtain the same outputs while mitigating the risks outlined above was discussed, and the option of using other bodies such as GFRA to connect two partners was suggested. The group recommended to proceed with caution and to report back to the next Session on the outcome of the first round of the FASTA process. Additional pathways to disseminate the PCP-FMD framework The group discussed how the high demand for training on the PCP-FMD (and other aspects of FMD management) by the partners in the Global Strategy and FAO and OIE MS could be met. This demand is not only originating from the national veterinary services but more and more from local veterinary services, private veterinarians, farmer groups, technical support staff of dairy cooperatives, and veterinary and livestock training schools. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

15 What are alternatives for achieving greater uptake and application by regional and national practitioners in disease management?. The financial resources available within the EC/EuFMD programme are fixed and very limited and so highly efficient ways of working are required. From the experience of the past few years the EuFMD training team suggests the following: Low cost, improved access to learning: - continued development of PCP-FMD e-learning modules for the global audience, and the process of establishing a Knowledge Bank including Job-Aids, and throughout the component work-plan, webinar series are offered relevant to the various regions. Widening participation: supporting a PCP practitioners community to include any person working with livestock and encountering FMD - EuFMD has been approached by the University of Tripoli, Libya to develop and support Continued Professional Development (CPD) training as means to offer training and expertise on FMD control for veterinary practitioners. As a result, EuFMD is considering so called Partnerships with Universities under its work-plans 2.2 and 2.3. It will be a means to reach out in a sustainable and practical way to those people working with livestock directly. Greater emphasis on CPD: CPD in the EU is a usual requirement for veterinarians but is very limited in neighbourhood countries and developing regions. Veterinary Statutory bodies have a role in setting requirements. Greater availability of CPD relevant to public and private management of epizootics/fmd will assist updating of the thousands of vets in practice in neighbourhood countries. -Does the OIE have information on how best to include Veterinary Statutory Bodies in promoting CPD? Funding: The above-mentioned routes and delivery of training for the practitioner community requires additional funding by other sources. -A funding basis could be that the user and member of such community pays for him/herself, or donor support is found for the outreach to practitioners. From the discussion with the members of the Executive Committee, it was concluded that there is General support for EuFMD to further explore alternative routes to disseminate the PCP-FMD approach. The broadcasting of webinar series, the development of e-learning modules and courses, establishing a Knowledge Bank including Job Aids was supported as a good example of using modern technology to disseminate the PCP-FMD approach to large groups of stakeholders from both the public and private sector. It was however stressed that o o EuFMD has to remain focused on its objectives under its mandate with regard to Pillar II and III. Alternative routes are to be in parallel with support to strengthening the capacity of the national veterinary services as this is a similar important part of the Global Strategy of FMD control. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

16 o Training and support through partnerships with Universities must keep in mind the local situations to safeguard its application in the local context of a country (academic institutions are not the competent authorities for notifiable disease management). There was support to have statutory boards involved when discussing support to CPD development and delivery. Support to pursue cost recovery options including charges for training provided to the practitioner community. Here, EuFMD can further elaborate its policy on user-fees being charged directly to practitioners or through third-party organisations (including international organizations). Item 5: FMD situation Global and Regional a) Report of the FAO World Reference Laboratory (WRL) for FMD, Pirbright Dr Don King, head of the WRL, presented the report to the Executive Committee (Appendix 6). The regular Report forms part of the requirements of the EC funded Contract between EuFMD and Pirbright (the status of this Contract is discussed later under this Item). He outlined the considerable changes in the global FMD situation since the last Executive Committee Session. The most significant involve long distance jumps of FMD topotypes from one pool to another, notably into the Middle-East and North Africa. These jumps call into question the vaccine selection in those regions which are usually based on the prevalent local virus circulation. The unexplained circumstances of these long distance virus movements also raise questions for European risk assessment. The importance of outbreak investigations to ensure unusual patterns (suggesting new strains) followed by genotyping with rapid feedback of data to inform control efforts was emphasised. A higher rate of typing of outbreaks in the European neighbourhood is needed if new incursions are to be picked up quickly, and greater attention to the Gulf /Arabian Peninsula countries as incursion points. Epidemic situation: the type O/Ind/2001 virus has continued to spread westwards, after several months when its presence in Tunisia/Algeria was not reported, causing outbreaks in Morocco, and has also now spread east from India into Vietnam and Lao PDR. There is a good match between existing vaccines and this virus strain. Phylogenetic analysis suggests that there have been multiple escapes of this virus from the Indian subcontinent. The type A G-VII virus strain has spread into Saudi Arabia, Iran, Turkey and Armenia, in another example of rapid and unexpected virus spread between pools. There is a poor in vitro match between this virus and many commercial vaccines; this poses a considerable risk to Europe. An in-vivo vaccine challenge study is currently underway in Pirbright and the results will be communicated to EuFMD in April when it is complete. There are promising reports from Turkey that the novel vaccine produced by the SAP Institute against this strain is effective, and bovine vaccinal serum should soon be sent from the SAP Institute to Pirbright for inclusion in the next vaccine matching panel. The situation in East Asia was described, where three virus lineages continue to cause outbreaks: O/ME- SA/PanAsia, O/SEA/Mya-98, and A/Asia/Sea-97. These viruses are thought to spread into East and Central Asia from South-East Asia. [Note: shortly after the Session, WRL reported the detection of O /MESA/Panasia in Israel and Palestine, an apparent jump from South-East Asia]. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

17 The vaccine bank recommendations from WRL to the ExCom are unchanged, but the gap in vaccine availability for A/Asia/GVII was emphasised; the current challenge studies should help identify if the current set of high priority antigens provide acceptable levels of protection. The Annual Meeting of the OIE/FAO FMD Laboratory Network (supported by OIE and EC/EuFMD, the latter under Component 3.3) had been held in Belgium in November 2015; this included working group meetings on nomenclature and post-vaccination monitoring, discussion of global surveillance and changing risk pathways, and harmonising and improving laboratory capacity. Training activities being conducted by WRL were described, including an OIE twinning project with NAHDIC Ethiopia and the development of e-learning materials. The recent outbreaks of swine idiopathic vesicular disease, caused by Seneca valley virus, in the United States was described. This has caused a considerable increase in the number of FMD suspect cases reported there, since the clinical signs of vesicular lesions are similar. The relevance of this for differential diagnosis in Europe will be disseminated to NRLs of EU member states at the EURL FMD meeting in May. Discussion Dr Füssel (EC) commented on the significance of virus strains emerging from India and how useful it would be to have more information available on the FMD viruses circulating there. Dr Lubroth (FAO) noted that the FAO have also advocated for improved surveillance in India and sharing of virus data, including through the SAARC body and the FAO regional unit. Dr Maud (EuFMD) referred to the work jointly conducted by the FAO Kathmandu office and EuFMD in the context of the real-time FMD training courses in Nepal, whereby virus isolates from outbreaks are collected and made available for further analysis; the value of this activity to provide a window into virus circulation in India was highlighted. Conclusions: 1. The recent jumps of infection from South Asia into the Middle-East, and the rapid spread between countries in the south-eastern European neighbourhood, should be noted by the member states as a major cause for concern. 2. Laboratory and field studies on the level of protection provided by type A antigens in the EU bank and the new A G-VII vaccines are urgently required. The possibility to undertake such studies in the field in Iran or Turkey should be vigorously pursued. 3. Greater attention must be given to obtaining up to date information on virus circulation in South Asia, especially India, and the identification of effective vaccines. The real-time training programme in Nepal has provided a useful opportunity to ensure samples are collected and submitted for typing, but a more strategic approach to ensure active South Asian participation in FMD surveillance is required. The Regional Support Unit (RSU) to SAARC countries could play an important role, and South Asia should be prioritised for more attention under the Pillar III networking and training action plan. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

18 b) Report on the FMD situation in Turkey and neighbours: (WELNET report) The report on the FMD situation in Turkey and neighbours was presented by Dr A.Naci Bulut, Şap Institute (Appendix 7), on behalf of Dr Nihat Pakdil, Deputy Secretary of Ministry, The Ministry of Food, Agriculture and Livestock, Turkey. Dr Bulut reported that in the period 1 January to 1 October 2015 a total of 62 outbreaks (O, A, Asia 1 serotypes) had been reported in Turkey. The situation changed from early October; on the 9 th October 2015, molecular analysis of a serotype A sample that had been collected from an outbreak investigated in Van province on 29 th September 2015 which indicated the incursion of a new strain of serotype A FMD virus. The genetic sequence of this virus strain, subsequently referred to as serotype A G-VII, was extremely different (21.5% by sequence) from the serotype A FMD strains previously circulating in Turkey during An emergency response to the new incursion was initiated, involving animal movement restrictions, active surveillance and rapid production of a new vaccine. A monovalent vaccine for the new serotype was available for in vitro vaccine matching and quality assurance on 10 th November 2015, and first used in the field on 24 th November Turkey s spring vaccination campaign was brought forward, and following initial emergency use of the newly manufactured monovalent vaccine, a tetravalent vaccine including the new strain has now been produced (O Panasia/, A (AsiaGVII, A Iran05/A Tur14 and Asia1/SINDH08). Dr Bulut reported that the number of outbreaks reported due to Serotype A gen VII rose very rapidly, with a total of 126 outbreaks reported in November and 265 in December due to the new serotype. Outbreaks occurred in all geographic regions of Anatolia, but no outbreaks were detected in Turkish Thrace. Figure 1: FMD outbreak data from Turkey, indicating outbreaks due to Serotype A (red dashed line). Reproduced with permission from presentation given by Dr A Bulut to the Executive Committee 91st Executive Committee of the EuFMD, The Hague, 9-10 March

19 Figure 2: Geographic distribution of outbreaks reported in Turkey due to Serotype A Gen VII FMD virus in November and December 2015, reproduced with permission from the presentation given by Dr A Bulut to the Executive Committee. The Spring FMD vaccination campaign was brought forward to begin December To date a total of 15.5 million doses of tetra-valent vaccine have been administered giving vaccination coverage of 93%. Booster vaccination for primo-vaccinated cattle in the Marmara and Aegean regions has been implemented and a vaccination campaign is planned to be carried out three times in these regions in Movement restrictions and closure of markets has been strictly enforced in affected areas. Surveillance, outbreak investigation and awareness raising activities have also occurred. In the Thrace region, activities as part of the EuFMD surveillance programme have continued and in addition clinical surveillance has been conducted three times by central surveillance teams. The number of reported outbreaks is reduced with 83 reported in January 2016 and 33 in February Discussion Dr Alf Füssel thanked Turkey for their good and rapid response to this outbreak. He emphasised, supported by Dr Spiros Doudounakis, the importance of ensuring that Turkish Thrace maintained its FMD free with vaccination status. Dr A. Naci Bulut responded that the FMD free status of Turkish Thrace was extremely important, not only in preventing incursion of FMD to neighbouring Member States, but also to Turkey itself, and therefore every effort would continue to be made to protect this region and continue surveillance activities. Dr Chris Bartels proposed that the rapid epidemic spread of this novel strain, combined with large amount of data available presented a unique opportunity to study the evolution of the outbreak and mechanisms of FMD transmission in Turkey. Dr Don King agreed, mentioning that genetic sequencing could assist in these epidemiological studies, but that such a study would require adequate funding, above that available from EuFMD s research funds. Dr Füssel agreed that such studies would be extremely important, and might build on existing modelling studies carried out in Turkey. Dr Bulut supported the need for studies within Turkey, but emphasised that investigating the source of the incursion into Turkey, and drivers for disease incursion into Turkey, such as meat price data, is also important. The Secretariat were requested to follow up to investigate sources of funding and investigators to carry out such studies. Dr Jenny Maud mentioned that the Secretariat recognised the need for in vitro and field verification of the effectiveness of the newly produced Turkish vaccine strain. Iran had been identified as a suitable location to carry 91st Executive Committee of the EuFMD, The Hague, 9-10 March

20 out field vaccine effectiveness studies during the recent visit of Drs Sumption and Lyons, and Turkey had been requested to provide a small amount of the Sap institute vaccine (approx doses) to facilitate such studies. Dr Bulut was aware of this request, and had forwarded it to the Turkish ministry for approval. Conclusions 1. The SAP Institute, Turkey, is to be commended for the very quick development of a homologous vaccine to the epidemic type A G-VII strain, and the GDFC for bringing forward the spring campaign to ensure early, national re-vaccination, a very major logistical and practical achievement. 2. As the detection of the new strain and the initiation of vaccine development occurred before the international reporting of detection of the new strain, the Executive must remind its member states of the obligation to report epidemiologically significant events to the OIE and, under its mandate, also to the EuFMD. 3. The SAP Institute, as leader of the WELNET, together with the WRL and FGI-ARRIAH, had provided valuable information in English and Russian to the FMD laboratory network in neighbouring countries in West Eurasia and the Middle-East. 4. WELNET, working with WRL and FGI-ARRIAH, should urgently develop vaccine recommendations for West Eurasia for the upcoming Roadmap Meeting, and in future ensure it follows closely the situation in the Arabian Peninsula which now appears to be an entry point for infection to Turkey/Iran/TransCaucasus. FMD situation in the Caucasus countries A presentation (Appendix 8) was given by Dr Lebedev, speaking on behalf of Dr E. Nepoklonov. They had been invited by Dr Angot to present their position on FMD control given the epidemic development in the Trans- Caucasus, particularly the first case in Armenia for over a decade, related to the deteriorating epidemic situation in late In their proposal they recalled the long history of EuFMD implementing a disease control programme on behalf of the OIE/FAO/EC Tripartite, with Russian Federation vaccine used in the buffer zone from 19 to Their proposal was for a revival of a regional programme, with co-ordinated efforts in the territories bordering Georgia, Armenia and Azerbaijan, including the Russian Federation, Turkey and Iran, creating a new buffer against further spread of FMD using uniform FMD vaccine comprising the vaccine strains most relevant to the risk. The proposal also involves agreement of the parties on surveillance (both active and passive), including monitoring investigations and disease outbreak investigations and scientific and technical cooperation in the following areas: training of staff members (diagnosis, epidemiology, clinical diagnosis, etc.), risk assessment, epidemiology, also assessment of the disease risks and management options where susceptible wild animals are involved. They expressed their desire that their proposal would be able to achieve a functioning framework for the Caucasian Veterinary Services to work together, and to see progress of countries in the stages of the FMD Progressive Control Pathway (EuFMD/OIE/FAO). It would also be important for ensuring vaccine production is based on the most relevant FMD isolates before they reach the mentioned territories. It is also expected that over time FMD freedom of zones followed by country level is expected, with OIE recognition as FMD free zones or countries where vaccination is practiced (4th and 5th PCP stages). 91st Executive Committee of the EuFMD, The Hague, 9-10 March

21 Discussion Dr Angot welcomed the intervention and the proposal, which if it were to proceed would involve two EuFMD member states, Turkey and Georgia. The situation with epidemic spread of the type A G-VII has clearly indicated the importance of vaccine production centres in Turkey, Iran and Russian Federation to rapidly respond to the new threats, and these efforts could benefit all of Europe. The proposal though involves several countries not represented in the Session, but which are members of FAO and OIE, and a consensus would be needed that reflects the interests of those countries and the international organisations. Keith Sumption asked if the countries would be free to select and use their own vaccination strategies and programmes within a guidance framework, or was their proposal to supply vaccine with conditions in order to harmonise the programmes. The answer was that no decision had been made by the Russian Federation on supplying vaccine at this point, it was thought that common agreement would be sought with all CVO s on the vaccines to be used, with scientific support from EuFMD and FGI-ARRIAH. They also said that as the countries cover only % of entire animal population, there are gaps and international organisations should supply the rest to ensure 100 % coverage. KS stressed that the EuFMD experience with the buffer zone was that seropositive animals were found in the zone in every year, with some higher and lower risk areas recognised, and so it had to be concluded that entry of infection did occur, and at that time the buffer zones did not adequately manage movement controls. Very large buffer zones would therefore be needed, which could still be crossed by illegal movements in a few hours - a system which could be extremely costly and prone to failure. The benefits of alternatives involving greater internal control of movements must be part of the future solution. In summary, Dr Angot proposed a side meeting involving the representatives of the six territories, EuFMD, OIE, FAO and EC, during the OIE General Session held later on this year in May. The EuFMD could provide the Secretariat for the meeting, and would co-ordinate this with OIE, FAO and EC. c) Report on the situation in North Africa Dr Jean-Luc Angot presented the Report of FMD in North Africa in a presentation Support to REMESA, component 2.3 (Appendix 9). He started with an overview of the number FMD outbreaks reported in Tunisia (143 in 2014), Algeria (12 in 2015) and Morocco (15 between 28 October and 13 November 2015). The EuFMD workplan for REMESA had been developed during a workshop in Rabat, Morocco (24-26 August 2015) which had had the purpose to reach a common understanding on the difficulties associated with the control of the FMD incursion into the region in 2014 and The workshop provided recommendations in the fields of 1) strengthening prevention of incursions, 2) Strengthening FMD control, 3) Improving mobilisation of human and financial resources and 4) Strengthening of communication. From these recommendations, and based on previous activities and assessments, the Component 2.3 workplan was developed and includes: Improvement in short and long term management of the national FMD risk, with tangible indicators of progression along the PCP Pathway, towards OIE recognition of FMD freedom and a regional strategy for FMD control. The programme is based on the support to: 91st Executive Committee of the EuFMD, The Hague, 9-10 March

22 o o o develop, adopt and implement Risk Based Strategic Plans for FMD control in Libya and Mauritania, and the capacity to achieve and maintain PCP stage 3 or 4 in Morocco, Algeria, Tunisia; Implement a coordination framework in order to facilitate communication, review and guide upon activity implementation at national and regional level; Create a system to improve availability of disease risk information for planning of surveillance, control and vaccination programmes, and developing vaccine banks. All the activities and the related outcomes can help to directly or indirectly reduce the risk of FMD incursions into the EuFMD member states. Dr Jean-Luc Angot continued by going over the Status of activities. The issues brought to the attention for the Executive committee were Difficulties in Libya for RBSP and partnership with University of Tripoli (security and political instability). See the group discussion (group 2); Difficulties in Mauritania to further develop the RBSP due to lack of commitment of Veterinary Services and pending payments; Greater involvement of technical officers from REMESA countries, through contracting STPs from North Africa countries: Karima Ouali from Algeria from March to August to support the activities planned under component 2.3 and Mounir Khayli from Morocco from March to May to provide assistance to the surveillance programme for FMD in Morocco. Dr Angot concluded that the 2.3 workplan is established according to the needs and supporting the development of a regional strategy for FMD control. Key elements are risk-based surveillance and early warning system, selfassessment on vaccination programmes, emergency preparedness, opportunities for exchanging information and improving networks and trainings. Last but not least, the ground is laid for close collaboration and coordination with FAO, OIE and REMESA countries. Discussion The mechanisms by which infection of the Indian type O strains initially spread to Libya was raised, and the lack of apparent detection of FMDV circulation in Algeria preceding the outbreaks in Morocco. Dr Ripani provided additional information in his presentation on these points. The Session noted with appreciation the work undertaken, including the importance of support to improvement of surveillance in regions recently affected by FMD in North Africa and where the possibility of circulating infection remained. d) World Reference Laboratory (WRL) contract Dr Ryan (Chairman, STC) summarised this item. The previous contract between WRL and EuFMD concluded in October 2015, with the final payment under the letter of agreement made after the final report had been received. In good faith, and as good partners, the WRL have continued their activities in line with the previous contract, including funding the OIE/FAO FMD reference laboratory meeting in November A draft letter of agreement for the renewed contract is under preparation, which will include activities from components 1.7 and 3.3 of the strategic plan; this will be discussed between the Secretariat and Don King (WRL) in the coming days, and in line 91st Executive Committee of the EuFMD, The Hague, 9-10 March

23 with discussions with the Financial Unit of DG-SANTE, will be reviewed before finalisation by the latter to ensure there is no perceived or actual double funding of activities under the EU-RL and FAO/EuFMD contract. Discussion Dr King commented on the delay in renewing the contract with the WRL; there was a risk that financial controllers in Pirbright may not be willing to continue to provide services in the absence of a contract; there was also concerns in Pirbright that the new contract must be retrospective in order to refund the cost to Pirbright of providing services to EuFMD during the period between contracts. Dr Füssel (EC) confirmed that the renewed EC contract with EuFMD would be retrospective, and so the money could therefore be used by the Secretariat to pay WRL for work already conducted as agreed. Item 6: Items proposed by Gf-TADS Partners A joint presentation (Appendix 10) by Juan Lubroth (FAO), Jean Pierre Dop (OIE) and Alessandro Ripani (OIE). Dr Lubroth started with an overview of the FAO support to FMD control, which supports the reduction of risk to EuFMD member states. In 2015, FAO through Technical Cooperation Projects (TCP), Trust Funds (TF) has supported FMD control in various regions of the world. This included Emergency assistance or support on FMD control in North Korea, Uganda and Zimbabwe; Development of National Control Program for Foot and Mouth Disease in Pakistan; Building resilience and self-reliance of livestock keepers by improving control of Foot-and-Mouth Disease (FMD) and other Transboundary Animal Diseases (TADs) Afghanistan; Foot-and-Mouth Disease Control in Southeast Asia through Application of the Progressive Control Pathway", within the framework of "Improving National Preparedness for Transboundary Animal Infectious Disease in Developing Countries in Southeast Asia". As well as numerous projects on strengthening of the veterinary services which are in line with the 3 rd component of the Global Strategy for FMD control. Since 2012, 11 regional roadmap meetings were convened in Asia and Africa. This is supporting gradual control of FMD by the approach of the PCP-FMD. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

24 Figure 3, Regional roadmaps convened since 2012 With regard to the Global Strategy for FMD control, Lubroth indicated that global FMD control seems feasible and that the PCP-FMD approach and the reinforcement of veterinary systems are gradually gaining acceptance. Currently, 60 countries are engaged and 42 countries are closely monitored with notable evidence of advancement. However, political will and engagement of international and regional organizations and development partners are crucial to the startup and sustainability of FMD control and funding is needed to support the global strategy, particularly those countries at lower PCP stages. A welcome development was that roadmap meetings are being attended by third parties especially in West Eurasia and East Africa which may be a show of interest by potential donors. Concurrently, these meetings demonstrate challenges in different areas such as diagnostics (for instance the capabilities to carry out sustainable surveillance, field investigations and collection and shipping of samples, laboratory biosafety and biosecurity and equipment and reliable flow of diagnostic supplies) and on vaccine and vaccination related issues such as low coverage, vaccination regimens for small ruminants, risk-based vaccination programs and use of good quality vaccine. Regional plans are necessary to address FMD control for hot-spots in regional ecosystem and their (re-) emergence), to establish concerted regional control plan with examples in Southern America (PHEFA) and South-East Asia (SEACFMD) and to understand animal movement patterns and value chains between countries within a region. Dr Juan Lubroth emphasized the need to be able to convince decision-makers on allocating budget on animal health related issues. FMD control is one of a number of competing priorities and may be overlooked given other disease concerns. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

25 Dr Jean-Pierre Dop continued the presentation with listing the priorities for the FAO/OIE FMD Working Group in These started with PCP Training for FAO and OIE staff to improve the awareness, and increase the appropriate application of the PCP-FMD tool, to clarify the link between the PCP-FMD and PVS tools under the component 2 of the Global Strategy and to clarify the relation between the PCP-FMD tool and the OIE procedure for endorsement of official control programme for FMD and for recognition of FMD free status. The ultimate goal is to have all regional / sub-regional officers being able to provide guidance to countries and to better follow-up their respective regional roadmap. For the long-term to have regional officers apply such risk management approaches to other threats of animal origin. Revision of the PCP-FMD guidelines and associated questionnaires, by building on the experiences gained and to include Component 2 of the FMD Global Strategy (Strengthening Veterinary Services) Guiding materials for FMD control plans required such as templates for control plans - to support countries willing to progress to PCP Stages 1, 2 and 3 and to advance in their PCP stage. Examples are the postvaccination monitoring (PVM) guidelines (soon to be published) and the socio-economic guidelines, to guide countries to: Need for Regional Leading Laboratories in particular in North Africa, Eastern African and Western Africa. These need to be rrecognized and nominated by the region while support may be expected from the Working Group to the process of drafting criteria and development of the nomination process. Such Regional Leading Laboratory will benefit the region by facilitating access to training and diagnostic reagents and proficiency testing. [Note on the last: the OIE/FAO Working Group had agreed Regional Support Laboratories in 2013 to be: Kenya (Embakasi), Ethiopia (NAHDIC), Nigeria (Vom), and Senegal, based on nominations from the regions. On this basis EuFMD had provided support under its component 3.3. These cover East and West Africa only]. Dr Jean-Pierre Dop continued to outline the OIE activities relevant to FMD control at global level. He referred to the current revision of the Code and Manual on international standards. Additionally, Dr Dop mentioned the update of official status recognition and endorsement of official control programs. As can be seen from the global map in Figure 4, the endorsed status of Algeria was withdrawn recently (February 2016) after withdrawal of the Tunisia endorsed control programme in September An OIE steering committee is currently elaborating the details of establishing OIE supported vaccine banks. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

26 Figure 4, Endorsement and recognition Dr Alessandro Ripani from the OIE sub-regional representation for North Africa in Tunis, Tunisia continued to present FMD activities in North Africa. He started with reviewing the FMD situation in the region. Serotype O, strain O/ME-SA/Ind-2001 started circulating in 2014 in Tunisia and Algeria after previously being introduced in Libya in In November 2015, this strain was detected in Morocco. It seems likely that this strain originates from the Indian subcontinent and has reached North Africa through trading routes in which the Middle East is involved. Serotype SAT2 was notified in Mauritania in 2015, 9 years after the previous FMD notification from Mauretania. The lessons learnt from the FMD epidemic in North Africa are the difficulties to contain animal movements between and within countries affected. This involves difficulties with raising awareness with animal traders, with having appropriate vaccines available immediately and difficulties in implementing regular active surveillance in the affected countries. Obviously, the political instability in Libya is posing a challenge for a regional approach to control. Dr Ripani continued to elaborate about the REMESA activities, in particular on the decision by the Joint Permanent Committee (JPC) during the 9 th meeting held in Tunis. The OIE was entrusted by REMESA Countries to implement a regional bank for North Africa of vaccines and antigens for FMD to allow access to high quality vaccines or antigens for the countries of the Region complying with intergovernmental standards - in particular in emergency situation - through an international call for tender prepared by the OIE. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

27 This project is in progress and the countries recommended to establish a specific steering committee for the vaccine bank that would associate REMESA member countries with representatives of the UMA secretariat, FAO sub regional office for North Africa, EuFMD as well as donors. At the last JPC meeting in Algiers (24-25 November 2015), the importance of establishing a regional vaccine bank for FMD in the REMESA region was re-iterated, along with a harmonized vaccination strategy among the countries and an effective livestock animal identification (traceability of the animal movements). Based on these recommendations, OIE office in Tunis plans to organize a workshop dedicated to elaborate and to be agreed on a harmonized and feasible vaccination strategy for FMD to be presented at the next REMESA meeting. The major elements to be discussed and agreed during the workshop are as follows: Which species need to be vaccinated and at what ages; which serotypes need to be used; What is the best ttiming of vaccination programme. This workshop is scheduled for 30 and 31 March for which EuFMD is invited to provide a technical expert. A second workshop will discuss livestock identification systems in cattle and small ruminants. Discussion The situation with Regional Leading Laboratories (RLL) was discussed. Clarifications were needed on terminology and process, since Regional Support Laboratories (RSLs) had been identified in East and West Africa under the FAO lead regional laboratory and epidemiology networks. Dr Juan Lubroth emphasized the role EuFMD may have by setting criteria for the nomination process for the RLL and by providing support in training and access to diagnostic reagents/proficiency testing. The need to build up the cadre of expertise to provide strategic guidance to countries on FMD management was emphasized. FAO and OIE receive continual requests for support and are unable to field the teams required on short notice. The training offered by EuFMD could assist to develop this, but attention is needed to ensure that a cascade of training is feasible. New options to explore national capacity development by the low cost roll out of the virtual training must be considered. The progress to develop a harmonized strategy on vaccination and a vaccine bank for North Africa was discussed. Dr Angot, Chairman, thanked the FAO and OIE for their joint presentation and for the positive development of the working relations with EuFMD, and the efforts to ensure commonly agreed workplans under Pillars II and III. Item 7: Standing Technical Committee (STC) Dr Eoin Ryan (STC Chair) presented the report (Appendix 11). The STC had held a meeting in Rome on 4 th February, where the EuFMD workplan was presented and discussed. The risk posed to program delivery by the delay in obtaining funding from DG-SANTE was noted by the STC. The benefits of partnerships to EuFMD program delivery were discussed, including the Australian/New Zealand partnership and the additional funds received from the UK, Spain and Germany for tailored training courses. In relation to the output evaluation methodology for the work program, the STC noted that for Pillar III, this may not be fully appropriate since Pillar III activities involve cooperation with others (FAO, OIE, national partners) and so input and activity evaluation would also be appropriate in this case. The benefits to the program of cross-cutting activities such as training (developed for Pillar I but used in Pillar II and III), risk-based surveillance (developed in Thrace, now being looked at for Pillar II areas), and alignment with programs under the Better Training for Safer Food (BTSF) were noted. An update was provided on the tasks assigned to the STC at GS41. The diagnostic bank proposal which had been outlined by Dr Ryan at the 90 th ExCom meeting, and further refined during the group discussions at this meeting, was discussed and the revised proposal based on the group work endorsed. For vaccination-to-live issues, a sub- 91st Executive Committee of the EuFMD, The Hague, 9-10 March

28 group of the STC and SCRPD will be convened by Stephan Zientara (ANSES, STC) to explore further with a view towards reporting back to the ExCom and Secretariat; it is proposed to hold a meeting of this sub-group in ANSES shortly. The impact of the new Animal Health Law on contingency planning and business continuity planning and the intersect with the need for guidelines for farm/industry biosecurity was outlined; this was to be explored further by Dr Rassow (Germany, STC). However, Dr Rassow has now resigned from the STC due to a change of duties in work. Regarding the options for FMD control in wildlife, Dr Ivanov (Bulgaria, STC) has attended the relevant simulation exercise in Bulgaria and will report back. Regarding the biorisk management group, the sad loss of Dr Bernd Haas was noted. The STC recommendation to the Executive Committee was that Katrin Summermatter (Switzerland) and Sebastian Allix (France) be invited to join the BRMG. The priorities for the Fund for Applied Research had been agreed by the STC; it was emphasised that the FAR is the only FMD-specific research fund at European level. The priorities proposed by the STC are: Tools to assist modelling FMD spread with respect to national data compatibility issues; The practical application of the latest biosecure FMD sample transport research; The application of FMD impact calculators to contingency planning; The requirements for approving FMD marker vaccines within the EU; Tools to manage the spread of FMD in wildlife. Open Session: The proposal for the 2016 Open Session of the STC and Special Committee on Research was put to the Executive Committee. The STC meeting had reviewed the options identified in the Lisbon area of Portugal. A very suitable Conference facility in the historic port village of Cascais, Portugal had been found and the recommendation was to proceed with this choice, with dates of October. Regarding costs, the Conference is planned to be on a non-profit, cost recovery basis, and to ensure this, it would be needed to increase registration by 50 to 300/350/400 for early bird/regular/late registration. Given the expected interest in the STC day, a one-day registration option would be provided, at 150. The themes proposed are: Overall Title: OS 16 : The Practice of Innovation The Session would be divided into two parts, the STC led day and the Research Committee led Sessions. STC Day: Innovative ideas and options for FMD management Research Days: Globalising access to science and innovation: connecting livestock keepers and knowledge leaders. Discussion Dr King (WRL) indicated the importance of the Session for research students for their understanding of FMD policy, management and science, and asked if the cost for students could be reduced rate. This was agreed in principle, subject to the Secretariat examining the projected costs and it not adversely affecting the existing estimates. Dr Angot thanked Eoin for his report and the members indicated their appreciation of his work for the STC. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

29 Conclusion 1. The five proposed priorities for support under the Fund for Applied Research were endorsed. The proposal for the Open Session was supported. The Secretariat should ensure that as far as possible the Session was also available online as this had been a success in Item 8: Administrative and financial The Secretary outlined the financial status of the Funds under management (Appendix 2). Relating to the Administrative Fund (MTF/INT/011/MUL), this fund had been also used with the agreement of the Chairpersons to cover operational activities scheduled for performance under the EC contract, since 1 st October Of a total expenditure of USD 174,745 it is expected that when relevant expenditures are transferred to phase IV of the EC programme the remaining expenditure for 2015 will be USD 488,500. Dr Sumption detailed contributions received from MS to the Trust Fund. A total of USD 563,341 have been received, with USD 75,502 outstanding. Albania and FYR of Macedonia have outstanding contributions of greater than two times their annual contribution. The Emergencies and Training fund (MTF/INT/004/MUL) has received funds from Australia and New Zealand under the Nepal Real Time Training project, and also from multiple Lander in Germany to support attendance on a bespoke Real Time Training course. These contributions are received on a full cost basis, and have supported the recruitment of additional staff members and also the development of new training and e-learning content. Dr Sumption thanked Dr Juan Lubroth and Dr Berhe Tekola (FAO) for their assistance in securing new office accommodation at FAO headquarters after EuFMD were asked to vacate two rooms which had been used for Operations staff and STPs (8 persons). Discussion In relation to outstanding contributions from Member States, Dr Angot suggested that official letters be sent to Albania and the FYR of Macedonia requesting urgent payment. Dr Herzog commented that payment in instalments could be offered as a solution if necessary. Dr Füssel confirmed that DG Santé had agreed that the signature of the agreement will proceed as soon as possible and can be retroactive to the 1 st October st Executive Committee of the EuFMD, The Hague, 9-10 March

30 Item 9: Co-ordination, future meetings Dr Angot thanked Dr Bruschke and Dr Bouma for the hosting of the Session in very pleasant meeting facilities, and thanked all for their attendance and contributions to the discussions. In particular, he thanked Turkey for sharing of information and their response to the recent serotype A G- VII outbreaks. Dr Angot also thanked the representatives from the Russian Federation for their attendance and proposal. Finally, he acknowledged the excellent work done by the entire EuFMD team, in preparation for the meeting. Dr Angot proposed that the next meeting be held during September 2016 in Corsica, France, and all present agreed to this proposal. Subsequent to the Executive Committee meeting, the location and dates are now changed to Paris, France, September. 91st Executive Committee of the EuFMD, The Hague, 9-10 March

31

32 COLLATED APPENDICES

33 91 st Session of the EuFMD Executive Committee Adoption of the Agenda 9-10 March 2016 Ministry of Economic Affairs, Bezuidenhoutseweg 73, The Hague DRAFT AGENDA Day 1 2 Report on EuFMD activities since the 90 th session K.Sumption 3 Update and questions arising from implementation of the workplan a. Training Programmes b. Emergency Preparedness c. Progressive Control of FMD - in neighbourhood and in support of the Global Strategy d. Prioritization of Applied Research and Surveillance After review of the main questions arising, small group discussions to be held facilitated by Secretariat team with the members of the Executive responsible for each component plus the invited observers the latter are free to select the group most relevant to their interests. Short recap from Groups before closing of Day 1 Day Feedback Session from Group work 5 FMD situation - Global and Regional a. Report of the WRL b. Report on the FMD situation in Turkey and neighbours (WELNET Report) c. Report on the situation in North Africa d. WRL contract and the support to international surveillance (FAST process) Coffee break D.King Ö.Türkyılmaz J.Angot 6 Items proposed by Gf-TADS Partners This may include GF-TADS Europe, Reports of the Middle- East Roadmap, FMD working group, and reports for information. 7 Standing Technical Committee Report E.Ryan a. Report of meeting held in Rome, 4 th February b. Themes for the Open Session 2016, and OS16 arrangements Lunch break 8 Administrative and Financial EuFMD 9 Co-ordination future Meetings 10 Any other business Closure of the meeting

34 REPORT ON THE ACTIVITIES OF THE SECRETARIAT EuFMD Summary of the activities October 2015 February 2016

35 -Report on Activities of the Secretariat October 2015-February 2016 Summary 1. The 90 th Session of the Executive Committee was held at Monza, in Italy in September 2015, and the Report has been finalized, circulated for comment and published online. The recommendations and conclusions are given in Appendix The major FMD risk events of the period have been the epidemic of FMD serotype A (G-VII genotype), which has swept across the Arabian peninsula, and entered Turkey, Iran and Armenia, and against which no proven well matched vaccine exists; and the continuation of the type O epidemic in North Africa, affecting Morocco in October- November, 6 months after the last reported case in Algeria. These events have required urgent co-ordination and networking with countries and international laboratories to ensure coordinated efforts to identify vaccines and ensure countries at risk are better prepared. 3. Requests were received from Morocco for assistance on FMD laboratory support to surveillance (November), from Spain for an online training course in FMD emergency response (FEPc), at the GF-TADS Middle-East Roadmap Meeting in Doha (December; support to Lebanon and Jordan for formulating national risk based strategic plans), and from EC technical co-operation office (December) for a mission to Cyprus to review measures being taken to mitigate the elevated risk of incursion from Turkey. Following consultation with the Government of Cyprus, the mission (of the Secretary) was cancelled as the veterinary services of the RoC were not in support. 4. Phase III (10/2013 to 09/2015) of the EC funded work programme was operationally closed at the end of September 2015, upon the date fixed at the start of the agreement. Given delays to finalise the agreement on Phase IV, a request to EC to extend the Phase III had been made but received too late for the financial unit of DG-SANTE to process an extension, and instead, an informal agreement to backdate the start of the Phase IV to the 1 st October was agreed at meetings of the Secretariat with DG-SANTE. In the period since 1 st October, essential activities to implement the decisions of the 90 th Executive have been funded from the Administrative Fund of EuFMD, as an interim measure until financing of Phase IV is in place. At time of this report, the agreement with DG-SANTE had not yet been signed, so interim financing has been continued. 5. The above situation highlights the importance of the member states contribution to maintain the EuFMD, since the MS support the key professional staff and in this situation, also interim funding of essential EC programme activities. The non-ec funding (by member states additional contributions and AUS/NZ) has also been important to maintain certain activities and members of the team. These additional means of support have given EuFMD some resilience in times of stress. 6. The interim funding situation has been difficult to manage, but through a focus on virtual networking, e-learning, and consultation with the partners in each of the components, essential (and possibly improved) planning has been achieved, while delaying higher cost (travel, in country) actions until EC funds arrive. The focus has therefore been delivery of support at a distance rather than on by face to face training and workshops. 7. In the above, the two positions (Training Programmes Manager and Contingency Planning Officer, CPO) that were filled in September 2015 under Administrative Fund support, have been critical to implement the programme by virtual means, and have actually enabled a new programme of online training and networking (Practical FMD manager program) in English and Russian languages, to address common interests and needs across Pillar I and II. 8. The composition of the Secretariat is indicated below, and Phase IV team for implementing the EC project activities is given in Table 2. This model is proposed as the basis for Phase IV. Each Component has had a Manager, an operational budget (on the assumption that Phase IV will be signed with EC on the basis submitted) and a clear work plan and targets, and this has assisted the entrance and effectiveness of short term (six months) professionals in the team. 91 st Session of the Executive Committee of the EuFMD, The Hague, Netherlands, 9-10 March

36 9. EC program implementation, Phase IV, since 1 st October 2015 : Given the cash-flow limitations, priority for implementation was given to: - THRACE Component (Comp 1.3), given the LSD epidemic situation and from November, the new epidemic of type A in Turkey; - Training needs assessment to identify priorities of the 37 member states and circa 15 neighbourhood countries; - Emergency response to the resurgence of FMD in Morocco, and Turkey/Iran (Comp 1.6); - Supporting contingency planners and epidemic managers (Pillars 1 and 2), by online webinars and training. Activities have commenced under almost every component but major commitments (e.g. Pirbright Contract, research fund contracts) and new ACTIONS (Component 1.8) have been postponed until Funding is committed by EC. 10. Under Pillar I, the focus has been upon - Component 1.1, Training for prevention and response; delivery of a Europe wide online training courses; focus on needs assessment survey of the 37 member states; - Component 1.2, Contingency Planning the modeling networks and contingency planners webinar series; - Component 1.3, THRACE; supporting the national project staff in the 3 countries to work in surveillance, and supply essential diagnostics, plus upgrading and training on the new (Google-based) mapping and information reporting system. The Balkans (Component 1.4) work component has started with information gathering on the status of contingency plans ad operation manuals, collection of data on human resource capacities and expertise; there has been good regional take up of the webinar series on Practical FMD Management. Activities of the Research Fund (1.5) and Risk Assessment (1.8) have been postponed, though planning (and monthly reporting of the Global situation) have continued. 11. In support of Pillar II, of most significance has been : - Effort to uncover the extent the of the type A epidemic of Indian origin, its risk to Eastern Europe and North Africa, and co-ordination of the communication efforts to ensure better preparedness; - Response to the type O epidemic in Morocco; - the implementation of a webinar/training series for REMESA countries, including French and Arabic languages (Component 2.3); - implementing a programme in Russian language for Practical FMD management, with take up of West Eurasian countries; - re-invigorated Laboratory and Epidemiology networking in West Eurasia, following the type A epidemic, with Russian and English language joint online meetings; - Doha meeting of GF-TADS, FMD Roadmap progress in Mid-East, with support of EuFMD experts and requests to assist neighbourhood REMESA countries (Lebanon and Jordan). Delays in Pillar II include the training courses for Turkey, as a result of failure to receive assurances that trainees would be able to practice their training in FMD related activities. 12. In support of Pillar III, support has been focused to the Gf-TADS Working Group through development of e-learning on the PCP, and on development of a process for leveraging support to the European FMD reference centres to increase their partnership with endemic countries. Delays in Pillar III activities, as a result of funding issues, have been in the negotiation of a contract with Pirbright to manage the Global FMD ref Labs network (to replace the contract that ended 9/2015), and recruitment of an STP for Pillar III. 13. Monthly Global Surveillance Reports have been produced, managed by Teresa Scicluna, STP. In November 2015 a special warning message was sent out to Member States on the new epidemic situation in the mid-east with type A (India G-VII topotype); subsequent spread occurred to Turkey, Iran, and Armenia, bearing out the dangers in the warning. 91 st Session of the Executive Committee of the EuFMD, The Hague, Netherlands, 9-10 March

37 Programme for the Phase IV, agreement with the EC on support to activities of the EuFMD 14. Following the adoption of the Strategic Plan, at the 41 st Session of the EuFMD in April 2015, and its 16 components ( Outputs ), and the endorsement of the work plans at the 90 th Session of the ExCom, the Secretariat had meetings with the Financial Unit of DG-SANTE aimed at finalizing the agreement, in October Several clarifications were sought by DG-SANTE, and provided in a series of updated documents including spreadsheets giving the basis and estimates of expected expenditures of expenditures on every activity planned under the 16 components over the initial two year planning period. Other aspects clarified included Evaluation Process and costs, where DG-SANTE agreed with the FAO position of an evaluation managed by the FAO evaluation service on a jointly agreed basis with DG-SANTE. At time of report the Financing Agreement had not been signed but no issues of substance were recognized to remain from the FAO/EuFMD side. The informal agreement with DG-SANTE is that the operational start or expenditures can be backdated to 1 st October 2015, therefore covering expenses incurred from that date which are part of the agreed programme. The ExCom should note that operational opening of the project (when spending is allowed) normally cannot start until funds are received, and therefore DG-SANTE is requested to make the first instalment quickly after signature. Additional funding (Non-EC) pipeline 15. In line with EuFMD policy relating to full cost recovery (funding) of activities requested by MS or other parties, and following requests from the Spain (for an emergency course) and Germany, e-learning courses have been delivered for national training in UK and Spain, and Real-Time Training programme for Germany, with training in Germany and Kenya, has been delivered in February 2016 (and reported at the Session). Courses under the contract with Australia/New Zealand resumed in November 2015, six months after the earthquake, and went very well. EuFMD Program Report 16. The management responsibilities for the EuFMD program are shown in the Table 2. All staff since 1 st October have been supported from the Administrative or Special (Training) Funds, because of the situation with the EC Phase IV funding. The Short Term Professionals (STPs) assist with management in areas of their competence. Administrative Report 17. The Secretariat staff are listed below (as of September 2015). Technical team: Executive Secretary Training Programmes Manager Contingency Planning Officer Communications and Networks Officer Keith Sumption Jenny Maud Marius Masiulis (from 23 rd September) Nadia Rumich Short Term Professionals Artem Skrypnyk (Ukraine), to April 2016 Teresa Scicluna (Malta) Magdalena Gajdzińska (to 15 April 2016) Aysegul Kudu (Turkey, 3 months, October-December 2015) Anna Zradkova (Bulgaria) (to 17 May 2016) Note that the Turkish, Ukrainian and Polish STPs are the first from these countries. Consultants (Component Managers) Administrative team: Program Co-ordinator Finance Assistant Operational support team Fabrizio Rosso, Gunel Ismayilova, Chris Bartels, Kees van Maanen, Nick Lyons, Carsten Potzsch Cecile Carraz Silvia Clementelli Erica Tomat, Chiara Addari, Emmanuela Pirrello 91 st Session of the Executive Committee of the EuFMD, The Hague, Netherlands, 9-10 March

38 18. Office space: The EuFMD Secretariat were required by FAO to release the two rooms (8 desks) used in Building B. The rooms in Building B were required for FAO Strategic Programme teams after the recent restructuring exercise. With tremendous support from AGA (Berhe Tekola and Juan Lubroth), a solution was found that would, if carried through, also address the shortage of room allocation to the livestock division ( AGA) and the piecemeal arrangements of temporary offices scattered across FAO. As a result, EuFMD will have the use of 3 extra rooms, 2 situated together with Technical EuFMD / AGA division and 1 open office room for Admin in a different building and floor. (New locations summarised in Table 3.) HQ EuFMD Staff ROOM Name Org Grade COMMENTS/ D 730 ADDARI, Chiara AGAHD PSA/SBS EuFMD Admin Training support D 730 CARRAZ, Cecile AGAHD Consultant EuFMD Admin Program Co-ordinator D 730 CLEMENTELLI, Silvia AGAHD Consultant EuFMD Admin Finance Assistant D 730 PIRRELLO, Emanuela AGAHD PSA/SBS EuFMD Admin Meeting support D 730 TOMAT, Erica AGAHD Consultant EuFMD Admin Travel/Training Supervisor C 504 ZDRAVKOVA, Anna AGAHD STP Junior EuFMD Technical STP Jr (Pillar I) C 504 GAJDZINSKA, Magdalena AGAHD STP (Pillar I) 1.1 EuFMD Technical STP (Pillar I) 1.1 C 502 Mounir Khyli AGAHD STP (Pillar II ) EuFMD Technical STP (Pillar II) C 502 Karima Ouali AGAHD STP (Pillar II ) EuFMD Technical STP (Pillar II) C 502 Name to be confirmed AGAHD STP (Pillar III) EuFMD Technical STP (Pillar III) C 516 ROSSO, Fabrizio AGAHD Consultant EuFMD Technical Component M. 2.3 C 516 MAUD, Jenny L. AGAHD Consultant EuFMD Technical Training PM C 516 RUMICH, Nadia AGAHD Professional FAO staff EuFMD Technical Communications/Networks C 518 SUMPTION, Keith J. AGAHD Professional FAO staff EuFMD Technical Executive Secretary C 520 MASIULIS, Marius AGAHD Consultant EuFMD Technical Contingency PM C 520 SKRYPNYK, Artem AGAHD STP (Pillar I) EuFMD Technical STP (Pillar I) C 520 ISMAYILOVA, Gunel AGAHD Consultant EuFMD Technical Component M Short Term professionals (STPs): Artem Skrypnyk (Ukraine), will finish in Mid-April 2016, handing over responsibilities to Miriam Casey (Ireland) to manage Components 1.3 and 1.4, Thrace and Balkans. Assistant STPs (whose terms do not involve full management of Components) have included Aysegul Kudu for three months to develop the Turkish language training courses, and Anna Zdravkova to continue this for the Balkan and Thrace components. In addition we have Magdalena Gajdzinska to assist Jenny Maud in management of the Training for MS (Component 1.1). 20. New STPs in pipeline: Miriam Casey (Ireland), Malin Grant (Sweden), Mounir Khayli (Morocco), and Karima Ouali (Algeria), are expected to start in period March and April In the case of the first two REMESA STPs, they will have specialized roles in support of the REMESA workplan and follow-up to the workshop in Morocco on design and implementation of improved surveillance. 21. Administrative support: Currently, we have a Program Co-ordinator (Ms Carraz), a finance assistant (Ms Clementelli), and three team members (Ms Tomat, Ms Addari, Ms Pirrello) working on all the administrative and logistic issues of the EuFMD. Ms Addari is also assisting in Training Support for the e-learning courses. 22. Linkage of funding to positions under Phase IV Under GAF submitted to the EC, after signature of the new agreement the responsibilities for a. Supervision and management of each Output is summarized below. Consultants 1-4 refer to those whose Terms of Reference were submitted to FAO for clearance, and would provide longer term (11 month contract) support. 91 st Session of the Executive Committee of the EuFMD, The Hague, Netherlands, 9-10 March

39 b. Operational support: the GAF was cleared by FAO based on 5-operation support positions, of which 4 would be supported under the EC and one by the MUL/11.,BOLD script indicates positions funded under the EC programme, and italics those funded by EuFMD under MTF/INT/011/MUL. Component (Output) Number Output Supervisor Output Manager Lead - Network and training support 1.1 TPM (P3 EQUIV) STP 1 P2 (80:20 EC AND MUL/11) 1.2 ExSec (EXSEC (P5) CPO (P3 EQUIV) P2 (80:20 EC AND MUL/11) 1.3 CPO (P3 EQUIV) STP CPO (P3 EQUIV) STP EXSEC (P5) Consultant-2 P2 (80:20 EC AND MUL/11) 1.6 EXSEC (P5) 1.7 EXSEC (P5) Consultant2 1.8 EXSEC (P5) CPO (P3 EQUIV) 2.1 EXSEC (P5) Consultant Consultant-1 Consultant Consultant-1 STP3 2.4 TPM (P3 EQUIV) Consultant-4 P2 (80:20 EC AND MUL/11) 3.1 EXSEC (P5) Consultant 3.2 EXSEC (P5) Consultant EXSEC (P5) Consultant TPM (P3 EQUIV) STP4 Consultant-4 P2 (80:20 EC AND MUL/11) Key: EXSEC (P5 Animal Health Office, Executive Secretary) P2 (Network and Training Support Officer) TPM (Training Programmes Manager, consultant with experience/terms equivalent to P3) CPO (Contingency Planning Officer, consultant with experience/terms equivalent to P3) 23. Financial position The Secretariat manages three Trust Funds, for the Administration of the Secretariat (MTF/INT/011/MUL, contributions from the Member States), EC Program (MTF/INT/003/EEC) and an Emergencies and Training Fund into which additional contributions have been received for provision of training (MTF/INT/004/MUL). 24. Position of the Administrative Fund (MTF/INT/011/MUL). The expenditure in the calendar year ending 31 st December 2015 was USD 830,865. (Table 3) This includes USD 174, spent covering the implementation of the Phase IV of the EC programme (this figure includes to the end of January 2016). When the EC expenditures are back-charged to the Phase IV, the expenditure in 2015 is predicted to be circa USD 488,500. The balance at the end of the calendar year 2015 was 88,574 USD. The monthly rate of expenditure in 2016 relating to Phase IV is circa 50,000 USD and therefore on this basis, the balance in the TF will diminish by at least 50,000 USD per month while supporting the EC Phase IV activities, even when the contributions due in 2016 are received, since normal commitments from the 011 Fund are approximately equal to expenditure, as agreed at the 2015 General Session. 2. Position of the Administrative Fund (MTF/INT/011/MUL) Outstanding Contributions: The opening cash balance in 2016 was 125, Contributions outstanding previous years USD 95, and contributions expected for 2015 USD 555,692. Contributions received in 2015 related to previous years and 2015 amounted to 526, Contributions received in January and February 2016 Cyprus, Estonia, Italy, Latvia, Malta and Poland. 91 st Session of the Executive Committee of the EuFMD, The Hague, Netherlands, 9-10 March

40 Total Contributions owed USD 651, Contributions outstanding previous years USD 95, MS Contributions expected for 2015 USD 555, Received up to 31/12/2015 USD 526, Outstanding Contributions 2015 USD 125, Contribution Received up to (Cyprus, Estonia, Italy, Latvia, Malta and Poland) USD 37, Total Outstanding contributions at USD 75, Received up to relating to 2015 USD 563, MS with outstanding contributions greater than two times annual contribution: Albania USD 16,570 FYR of Macedonia USD 25,020 Table 4. Financial Statement Member States Contributions at Table 5. Financial statement Member States Contributions at Position of the Emergencies and Training Fund (MTF/INT/004/MUL). This Fund has received funds from additional contributions to cover training courses funded by member states and by Australia/New Zealand, and funds are sufficient to cover the commitment to the remaining courses to be delivered from the 2015/16 contract. The funds from the latter are handled under a subaccount ( Baby 01 ). In February 2016, a national real-time training programme was provided to Germany to train veterinarians in Kenya from all of their Lander. It was fully funded from these Lander (75,900 ). The Fund has been used to pay for a Full Time Training Development Officer in 2014 and up to August 2015 (Jenny Maud) who manages Component 1.1, a considerable gain to the EuFMD and a saving to the EC Fund. From August 2015, Jenny s position has been covered by the Administrative Fund, freeing up training funds to support a training administrator as an STP and, as required, temporary technical consultants to develop new content, such as module on emergency vaccination, and so these contracts contribute to strengthening the training course content for Member States and help subsidise the training programme for the MS. 26. Position of the EC Program Fund (MTF/INT/003/EEC). Phase IV Project financial position: Expenditure on Phase IV (presently covered from the Member States /011 Fund) at 15 th February 2016 was 133, 980 (Tables 6 and following). This is circa 4% of the total budget, over a period of 4 months (16% of elapsed project). This reflects delay in programming activities and major contracts until the Phase IV funding is signed. 91 st Session of the Executive Committee of the EuFMD, The Hague, Netherlands, 9-10 March

41 Table 2 Management Responsibility: Pillar and Component Managers EuFMD /EC Action (Phase III) BOLD= Continuity. Red= change. TSO: Training Support Officer. STP: Short term professionals. KS: Keith; NR: Nadia; FR: Fabrizio; JM: Jenny; AUS: Australian funds (to 12/2013) Component (Output) to 2016 Comment Pillar Comp Output Supervisor Manager Jan-June July-September October 15-March 16 J Maud J Maud Magdalena Gajdzinka I 1.1 Training-RT Jenny Maud STP Contingency E Calduch (Jan), Katie Vacant Marius Masiulis 1.2 Planning KS CPO: Marius Masiulis HICKEY (Feb-June) Mark Hovari (Jan), Milan Milan (to Sept) Artem Skypnyk 1.3 THRACE MM STP Pandurovic (Feb-) Mark Hovari (Jan), Milan Milan (to Sept) Artem Skypnyk 1.4 Balkans MM STP Pandurovic (Feb-June) 1.5 Res Fund KS K Sumption K Sumption K Sumption 1.6 Crisis KS 1.7 PTS KS Kees Kees AUS funds support the Training Officer to August 1.8 Surveillance Rep KS TBD Teresa Scicluna Teresa Teresa M. McLaws (assisted by G. Ismayilova STP to Gunel Ismayilova Gunel Ismayilova II 2.1 Turkey/GEO KS HQ based Consultant June 2015) Home-based Kees Kees Kees 2.2 Israel/Cyprus KS consultant KS F ROSSO assisted by F Rosso (part time) Fabrizio Fabrizio covered Ibrahim Eldaghayes this from Malta. 2.3 REMESA Part-time officer (Visiting Scientist) Jenny Maud Karima Ouali New STP position in 2.4 P2 Training STP Phase IV KS Isabel Gutierrez (to Rodrigo Nova Not filled III 3.1 Monitoring TBD March) KS Home-based Chris Bartels Chris Chris 3.2 PCP consultant 91 st Session of the Executive Committee of the EuFMD, The Hague, Netherlands, 9-10 March

42 Pillar Comp Output Supervisor KS 3.3 Global Lab 3.4 P3- Training Jenny Maud STP Component (Output) Manager Home-based consultant to 2016 Comment Kees Kees Kees TBD STP appointment to be made Feb st Session of the Executive Committee of the EuFMD, The Hague, Netherlands, 9-10 March

43 STATEMENT 1 MTF/INT/011/MUL - TF number EUROPEAN COMMISSION FOR THE CONTROL OF FOOT-AND-MOUTH DISEASE Financial Report from 1st January to 31 December 2015 USD USD Eur Eur Balance as at 1 January , , Interest received 0 0 Contributions from member countries and instititute 513, ,929 Project Income Earned (Child) Expenditure Salaries 212,176 3, ,958 2,934 Consultant 534, ,106 Contracts 7,874 7,087 Locally Contracted Labour 1,259 1,133 Duty Travel 88,068 79,261 Training 0 0 General Operating Expenses 7,203 29,763 6,483 26,787 Expendable Equipment 3,967 3,570 Non-Expendable Equipment 8,779 7,901 Total Expenditure 830, ,779 Balance as at 31 December ,574 79,717 The Financial Statements of the Commission are maintained in US Dollars in accordance with the accounting policies and administrative systems of FAO. The amounts stated in Euros, including the opening balance, have been converted from US Dollars at the average monthly UN Operational Exchange Rates for The average monthly UN Operational Exchange rate applicable for period to 31 December 2015 is USD 1: EUR st Session of the Executive Committee of the EuFMD, The Hague, Netherlands, 9-10 March

44 bl Table 4 - Financial Statement at Member States Annual Contribution Inter-Regional - European Commission for the Control of Foot-and-Mouth Disease (expressed in USD) Member Outstanding Contribution Received up to Outstanding Governments 31/12/2014 due for /12/ /12/2015 ALBANIA 12, , , AUSTRIA , , BELGIUM , , BOSNIA , , BULGARIA 51, , , , CYPRUS 4, , , , CROATIA , , CZECH REPUBLIC , , DENMARK , , ESTONIA 4, , , , FINLAND , , FRANCE , , GEORGIA , , GERMANY , , GREECE , , HUNGARY , , IRELAND , , ISRAEL , , ITALY 3, , , , LATVIA , , LITHUANIA , , LUXEMBOURG , , FYR of MACEDONIA 20, , , MALTA , , NETHERLANDS , , NORWAY , , POLAND , , PORTUGAL , , ROMANIA , , SERBIA , , SLOVAK REPUBLIC , SLOVENIA , , SPAIN , , SWEDEN , , SWITZERLAND , , TURKEY , , UNITED KINGDOM , , TOTALS 95, , , , st Session of the Executive Committee of the EuFMD, The Hague, Netherlands, 9-10 March

45 Table 5 - Financial Statement at Note that outstanding amounts in 2016 do not include 2016 contributions which are yet to be requested by FAO to the MS. Member States Annual Contribution Inter-Regional - European Commission for the Control of Foot-and-Mouth Disease (expressed in USD) Member Outstanding Contribution Received up to Outstanding Governments 31/12/2014 due for /02/ /02/2015 ALBANIA 12, , , AUSTRIA , , BELGIUM , , BOSNIA , , BULGARIA 51, , , , CYPRUS 4, , , CROATIA , , CZECH REPUBLIC , , DENMARK , , ESTONIA 4, , , FINLAND , , FRANCE , , GEORGIA , , GERMANY , , GREECE , , HUNGARY , , IRELAND , , ISRAEL , , ITALY 3, , , LATVIA , , LITHUANIA , , LUXEMBOURG , , FYR of MACEDONIA 20, , , MALTA , , NETHERLANDS , , NORWAY , , POLAND , , PORTUGAL , , ROMANIA , , SERBIA , , SLOVAK REPUBLIC , SLOVENIA , , SPAIN , , SWEDEN , , SWITZERLAND , , TURKEY , , UNITED KINGDOM , , TOTALS 95, , , , st Session of the Executive Committee of the EuFMD, The Hague, Netherlands, 9-10 March Tl

46 Table 6: 4 Months Expenditures - Activity Plan Oct. 15 Jan Months Expenses October January Months Activities - 2 years Programme Pillars Supervisor Overall PILLAR Manager Keith Sumption Components Beneficiaries 1.1.E-learning programme Components Managers Total Budget Allocated Phase IV 4 months Expenses Oct. 15 -Jan %16.7 of project completi on 467,716 5,890 1% Balance available (20 months) 461,826 Oct'15 Nov'15 Dec'15 FEPC EuFMD-wide Introduction of the strategy of EuFMD, EU, OIE, FAO for the control of Foot and Mouth Disease and legal framework, and introduction to the Progressive Control Pathway Jan.'16 E-learning FMD Emergency Preparation (English) Elearning Remesa FEPC course for EUFMD MS Feb.'16 (expenditure not transacted) FMD Management series - Introduction to RBSP overview, structure, importance, examples (Russian language) FEPC course for EUFMD Member States E-learning FMD Emergency Preparation (English) 1.1 Jenny Maud Training for Member States 1.2 Improved Contingency Planning Marius Masiulis 90,000 2,062 2% 87,938 HQ FAO meeting - Martin Blake Webinar - Contingency plans overview, structure, importance, examples (English language) +(Russian language) PILLAR I Supervisor Keith Sumption 1.3 THRACE Region Artem Skrypnyk 354,474 21,508 6% 332, BALKANS Region Artem Skrypnyk 178,120 4,283 2% 173,837 LSD and THRACE meeting, Alexandroupoli, Greece Mission to Prepare for Crossborder exercises for FMD and other and-mouth Disease Workshop Bulgaria-Practical Training of Wildlife Surveillance for Foot- wild animal diseases in the THRACE Management Meeting programme - Mission to Prepare for Crossborder exercises for FMD - and-mouth Disease Workshop Bulgaria-Practical Training of Wildlife Surveillance for Foot- Brescia c/o Izsler Laboraroty 1'650' EuFMD Fund for applied RESEARCH Global FMD Research Alliance- Hanoi, Vietnam Keith Sumption 301,930 5,377 2% 296, Emergency Response Keith Sumption 165,179 2,763 2% 162,416 Mission Iran (FOLLOW - UP on New developments with FMD Serotype A in the region FAO STC Standing Technical Committee OS Site ispection 1.7 Proficiency Testing Scheme Kees Van Maanen 46,500-0% 46,500 Bruxelle M.T Scicluna + K.Vmaanen 1.8 Risk Analysis and Communication Marius Masiulis 46,500 1,695 4% 44, SOUTH EAST EUROPE SEE/ West Eurasia Gunel Ismailova EuFMD- Epidemiology training in Turkey Oct 334,909 22,259 7% 312,650 WS on serosurveillance design Nov - Tblisi, Georgia Participation 1st Meeting Regional Disease Surbveillance Working Group Executive Committee Almathy Kazakhstan PILLAR II Supervisor Keith Sumption 848' South East MEDITERRANEAN SEM / Cyprus - Israel 2.3 Support to REMESA North Africa 2.4 Pillar II Training development and coordination Kees Van Maanen 175,239 14,677 8% 160,562 Fabrizio Rosso 198,049 15,833 8% 182,216 Chris BARTELS 140,500 28,962 21% 111,538 Palestine (C.Bartels K.V.Maanen) Remesa Algeria J-L-Angot F.Rosso MENA Roadmap Partnership between FAO and University of Tripoli - 17 Dec FAO HQ Regional ws in Jordan FAO Consultative Meeting (2.2/3.3) Webinar - Remesa Proc Kits Senegal 3.1 Support to Global progress monitoring Keith Sumption 50,495-0% 50,495 PILLAR III 3.2 Method and guidelines fo application of PCP- FMD Chris BARTELS 95,000 6,505 7% 88,495 Supervisor Keith Sumption 714' Laboratory Support FMD reference lab serv. support regional epidemio surv. lab networks Kees Van Maanen 476,692-0% 476,692 ME VAC Conference FAO Consultative Meeting Chris (2.2/3.3) 3.4 Global access to PCP-FMD training resources Chris BARTELS 92,500 2,018 2% 90,482 3'213'803 Total Budget Allowances ,213, ,830 4% 3,079,973 MTF/INT/011/MUL Title EuFMD Executive Committee Meeting & Workshop STC interview STP Pillar III - OS Site Ispection Trainings /Contributions Donor Australia Training Contributions(UK, Lebano, US, Spain, and Germany) Germany KTC 16 - Nepal KTC17 + PCP - Nepal E-learning FEPC (Australia) Precourse Germany E-learning FEPC (Spain)/NTC 23 Germany RTT Kenya 91 st Session of the Executive Committee of the EuFMD, The Hague, Netherlands, 9-10 March

47 Table 7: 4 Months Activity Plan March June Months Expenses October January 2016 Forecast 4 Months Activities - March - June 2016 Pillars Supervisor PILLAR I Supervisor Keith Sumption 1'650'450 PILLAR II Supervisor Keith Sumption 848'697 PILLAR III Supervisor Keith Sumption 714'687 Overall PILLAR Manager Keith Sumption Components Beneficiaries 1.1 Training for Member States 1.2 Improved Contingency 1.3 THRACE Region 1.1.E-learning programme Components Managers Jenny Maud Marius Masiulis 90,000 2,062 2% 87,938 Artem Skrypnyk 354,474 21,508 6% 332, BALKANS Region Artem Skrypnyk 178,120 4,283 2% 173, EuFMD Fund for applied 1.6 Emergency Response 1.7 Proficiency Testing Scheme 1.8 Risk Analysis and Communication 2.1 SOUTH EAST EUROPE SEE/ West Eurasia 2.2 South East MEDITERRANEAN SEM / Cyprus - Israel 2.3 Support to REMESA North Africa 2.4 Pillar II Training development and co-ordination 3.1 Support to Global progress monitoring 3.2 Method and guidelines fo application of PCP-FMD 3.3 Laboratory Support FMD reference lab serv. 3.4 Global access to PCP-FMD training resources Keith Sumption 301,930 5,377 2% 296,553 Keith Sumption 165,179 2,763 2% 162,416 Kees Van Maanen 46,500-0% 46,500 Marius Masiulis 46,500 1,695 4% 44,805 Gunel Ismailova 334,909 22,259 7% 312,650 Kees Van Maanen 175,239 14,677 8% 160,562 Fabrizio Rosso 198,049 15,833 8% 182,216 Chris BARTELS 140,500 28,962 21% 111,538 Keith Sumption 50,495-0% 50,495 Chris BARTELS Kees Van Maanen 95,000 6,505 7% 88, ,692-0% 476,692 Chris BARTELS 92,500 2,018 2% 90,482 3'213'803 Total Budget Allowances ,213, ,830 4% 3,079,973 MTF/INT/011/MUL Title EuFMD Executive Committee Meeting & Workshop Trainings /Contributions Donor Australia Training Contributions(UK, Lebano, US, Spain, and Germany) Total Budget Allocated Phase IV 4 months Expenses Oct. 15 -Jan %16.7 of project completion Balance available (20 months) 467,716 5,890 1% 461,826 FMD Management series-introduction to RBSP overview, structure, importance, examples (Russian) FEPC course for EUFMD Member States E-learning FMD Emergency Preparation (English) Webinar - Contingency plans overview, structure, importance, examples (English +Russian language) Tentative Greece Training in Paris-FR for Morocco with ANSES Izsler 7 kits Practical Epidemiology Training-Turkey - West Eurasia Roadmap - Kyrgyzstan Tentative Mission to Palestine Atelier EuFMD REMESA: Workshop in Rabat - FMD early detection and freedom confidence 91st ExCom - Den Haag, NL 2016 Germany E-learning FEPC(Spanish)/NTC 23 Germany RTT April.'16 May'16 June'16 Exercice Simulation FA Tunisie KTC 18 RTT Germany Post Course 91 st Session of the Executive Committee of the EuFMD, The Hague, Netherlands, 9-10 March March.'16 KTC 19 NTC 24 Kenya Tentative Simex TCC

48 Table 8: Balance by Pillar by Budget Line at Table 8 EURO PILLAR I PILLAR II PILLAR III ACTIVITY Account NB. Description 5570 CONSULTANT (Technical) III PILLARS Budget III PILLARS 4 mths Exp. % III PILLARS Balance Available 20 mths Pillar I Budget Pillar I 4 mths exps % 91 st Session of the Executive Committee of the EuFMD, The Hague, Netherlands, 9-10 March Pilar I Balance Available 20 mths Pillar II Budget Pillar II 4 mths exps % Pillar II Balance Available 20 mths Pillar III Budget Pillar III 4 mths exps 847,775 72, % 774, ,275 26,038 6% 389, ,000 41,502 15% 243, ,500 5,335 4% 142, ,195 26, % 701, ,200 10,167 3% 386, ,500 13,608 6% 227,892 90,495 3,188 4% 87,307 TRAVEL ,863 28, % 814, ,830 4,560 1% 335,270 91,500 24,387 27% 67, ,533-0% 412,533 CONTRACTS , % 292, ,000-0% 144, ,947-0% 125,947 22,500-0% 22,500 TRAINING 6000 PROCUREMENT EQUIPMENT 6300 GENERAL OPERATING TOTALS for III Pillars Activities HQ Staff and Support Cost Account NB. Description 5300 SALARIES PROFESSIONAL 5570 CONSULTANT (Operational) 6150/6160 REPORT COSTS PROJECT EVALUATION TOTALS for HQ Staff and Support Cost OVERALL III Pillars OVERALL TOTALS for III Pillars Activities TOTALS for HQ Staff and Support Cost 302,947 4, % 298, ,336 2,763 1% 207,573 60,952 1,5 3% 58,957 31,659-0% 31, , % 198, , % 144,728 43, % 43,560 10,000-0% 10,000 3,213, , % 3,079,973 1,650,419 43,578 3% 1,606, ,697 81,730 10% 766, ,687 8,523 1% 706,164 III PILLARS Budget III PILLARS 4 mths Exp. % III PILLARS Balance Available 20 mths Pillar I Budget Pillar I 4 mths exps % Pilar I Balance Available 20 mths Pillar II Budget Pillar II 4 mths exps % Pillar II Balance Available 20 mths Pillar III Budget Pillar III 4 mths exps % % Pilar III Balance Available 20 mths Pilar III Balance Available 20 mths 1, % 1, ,845-0% 114,845 50,4-0% 50,4 34,209-0% 34, ,354 35, % 248, ,164 16,203 12% 113,961 81,244 10,110 12% 71,134 71,946 8,947 12% 62,9 41, % 41,608 26,651-0% 26,651 7,359-0% 7,359 7,5-0% 7,5 524,515 35, % 489, ,660 16,203 6% 255, ,102 10,110 7% 128,2 113,754 8,947 8% 104,807 III PILLARS Budget III PILLARS 4 mths Exp. % Balance Available Pillar I Budget Pillar I 4 mths exps % Balance Available Pillar II Budget Pillar II 4 mths exps % Balance Available Pillar III Budget Pillar III 4 mths exps % Balance Available 3,213, , % 3,079,973 1,650,419 43,578 3% 1,606, ,697 81,730 10% 766, ,687 8,523 1% 706, ,515 35, % 489, ,660 16,203 6% 255, ,102 10,110 7% 128,2 113,754 8,947 8% 104,807 OVERALL - III Pillars 3,738, , % 3,569,227 1,922,079 59, % 1,862, ,7 91, % 895, ,441 17, % 810,971 TOTAL Project Servicing 261,683 Charge 7% GRAND TOTAL 4,000,000

49 Table 9: Balance by Component by Budget Line at Table 9 EURO PILLAR I PILLAR II PILLAR III PILLAR I IMPROVE PILLAR II REDUCE PILLAR III PROMOTE ACTIVITY Account NB. Description III PILLARS Budget III PILLARS 4 mths Exp. % Pillar I Budget Pillar I 4 mths % Pillar II Pillar II Budget 4 mths % Pillar III Pillar III Budget 4 mths % exps exps exps Budget mths Exp. % 1.1 Budget mths exps % 1.2 Budget mths exps % 1.3 Budget mths Exp. % 1.4 Budget mths exps % 1.5 Budget mths exps 1.6 % Budget mths exps 1.7 Budget % mths exps 1.8 % Budget mths exps % 2.1 Budget mths Exp. % 2.2 Budget mths Exp. % 2.3 Budget mths Exp. 2.4 % Budget mths Exp. Comp 3.1 % Budget mths Exp. % Comp 3.2 Budget Comp mths Exp. % Comp 3.3 Budget Comp mths Exp. % Comp CONSULTANT (Technical) 5900 TRAVEL 5650 CONTRACTS 5920 TRA INING 6000 PROCUREMENT EQUIPMENT 6300 GENERAL OPERA TING EXPENSES TOTALS for III Pillars Activities ,775 72, % 415,275 26,038 6% 285,000 41,502 15% 147,500 5,335 4% 142,000 1,330 1% 40,000 2,062 5% 173,275 17,403 10% 25,000 3,547 14% 17,500 0% 2,500 0% 2,500 0% 12,500 1,695 14% 140,000 17,457 12% 45,000 11,694 26% 50,000 7,776 16% 50,000 4,575 9% 25,000 0% 60,000 3,317 6% 25,000 0% 37,500 2,018 5% 728,195 26, % 396,200 10,167 3% 241,500 13,608 6% 90,495 3,188 4% 180,600 0% 25,000 0% 52,500 4,054 8% 57, % 58,100 5,377 9% 5,000 0% 2,500 0% 15,000 0% 77,500 4,802 6% 69,500 2,982 4% 64,500 5,824 9% 30,000 0% 25,495 0% 22,500 3,188 14% 25,000 0% 17,500 0% 843,863 28, % 339,830 4,560 1% 91,500 24,387 27% 412, % 40,000 4,560 11% 12,500 0% 7,500 0% 25,000 0% 208,330 0% 39,000 7,500 0% 35,000 0% 10,000 0% 9,000 0% 37,500 24,387 65% ,533 0% 25,000 0% 292, % 144, % 125,947-0% 22, % 70,500 0% 5,000 0% 35,000 0% 12,500 0% 10,000 0% 2,500 0% 2,500 0% 6,000 0% 60,586 0% 19,650 0% 32,711 0% 13,000 0% - 5,000 0% 10,000 0% 7,500 0% 302,947 4, % 210,336 2,763 1% 60,952 1,5 3% 31, % 7,616 0% ,3 0% 15,642 0% 500 0% 147,679 2,763 2% % 11,500 0% 8,052 0% 41,400 1,5 5% - - 2,500 0% 29,159 0% - 198, % 144, % 43, % 10, % 27,000 0% 7,500 0% 47, % 42,478 0% 7,500 0% 7,500 0% 5,000 0% 10,323 0% 23,037 0% % 10,000 0% 5,000 0% 5,000 0% 3,213, , % 1,650,419 43,578 3% 848,697 81,730 10% 714,687 8,523 1% 467,716 5,890 1% 90,000 2,062 2% 354,474 21,508 6% 178,120 4,283 2% 301,930 5,377 2% 165,179 2,763 2% 46,500-0% 46,500 1,695 4% 334,909 22,259 7% 175,239 14,677 8% 198,049 15,833 8% 140,500 28,962 21% 50,495-0% 95,000 6,505 7% 476,692-0% 92,500 2,018 2% HQ Staff and Support Cost Account NB. Description III PILLARS Budget III PILLARS 4 mths Exp. % Pillar I Budget Pillar I 4 mths % Pillar II Pillar II Budget 4 mths % Pillar III Pillar III Budget 4 mths % exps exps exps Budget mths Exp. % 1.1 Budget mths exps % 1.2 Budget mths exps % 1.3 Budget mths Exp. % 1.4 Budget mths exps % 1.5 Budget mths exps 1.6 % Budget mths exps 1.7 Budget % mths exps 1.8 % Budget mths exps % 2.1 Budget mths Exp. % 2.2 Budget mths Exp. % 2.3 Budget mths Exp. 2.4 % Budget mths Exp. Comp 3.1 % Budget mths Exp. % Comp 3.2 Budget Comp mths Exp. % Comp 3.3 Budget Comp mths Exp. % Comp SALARIES PROFESSIONAL 1, % 114, % 50,4-0% 34, % 29,865 0% 15,204 0% 20,091 0% 9,774 0% 15,204 0% 9,231 0% 272 0% 15,204 0% 20,091 0% 12,489 0% 15,204 0% 2,715 0% 2,172 0% 14,661 0% 4,887 0% 12,489 0% 5570 CONSULTANT (Operational) 6150/6160 REPORT COSTS PROJECT EVALUATION COSTS 283,354 35, % 130,164 16,203 12% 81,244 10,110 12% 71,946 8,947 12% 50,188 6,235 12% 13,856 1,726 12% 32,131 3,980 12% 14,898 1,867 13% 8,966 1,127 13% 2, % 1, % 6, % 25,785 3,205 12% 16,622 2,078 13% 17,820 2,219 12% 21,017 2,607 12% 21,479 2,677 12% 25,683 3,205 12% 12,500 1,550 12% 12,284 1,515 12% 41, % 26, % 7,359-0% 7,5 0 0% 4,249 0% 1,690 0% 4,739 0% 3,604 0% 3,145 0% 8,006 0% % 2,784 0% 1,974 0% 2,145 0% 456 0% 1, % 4, % Project Servicing Charge TOTALS 7% for 261,683 HQ Staff and GRAND TOTAL 524,515 4,000,000 35, % 271,660 16,203 6% 139,102 10,110 7% 113,754 8,947 8% 84,302 6,235 7% 30,750 1,726 6% 56,961 3,980 7% 28,276 1,867 7% 27,315 1,127 4% 19, % 2, % 21, % 48,660 3,205 7% 31,085 2,078 7% 35,169 2,219 6% 24,188 2,607 11% 25,134 2,677 11% 40,803 3,205 8% 22,266 1,550 7% 25,551 1,515 6% Support Cost OVERALL III Pillars OVERA LL - III 3,738, , % 1,922,079 59, % 987,7 91, % 828,441 17, % 552,018 12, % 120,750 3, % 411,435 25, % 206,396 6, % 329,245 6, % 184,916 3, % 48, % 68,490 2, % 383,569 25, % 206,324 16, % 233,218 18, % 164,688 31, % 75,629 2, % 135,803 9, % 498,958 1, % 118,051 3, % Pillars TOTAL 91 st Session of the Executive Committee of the EuFMD, The Hague, Netherlands, 9-10 March

50 Training 91 st Executive Committee meeting of the EuFMD Training Programmes Update Training Programmes Update Component 1.1 Training for Member States Jenny Maud 91 ExCom Hague, 9 10 March ExCom Hague, 9 10 March 2016 Training Programmes Update Training Programmes Update Component 1.1 Training for Member States Component 1.1 Training for Member States Component 2.4 Pillar II training development and co ordination Component 2.4 Pillar II training development and co ordination Component 3.4 Global access to PCP FMD training resources 91 ExCom Hague, 9 10 March ExCom Hague, 9 10 March

51 Training Programmes Update Infrastructure: staff; e learning website and knowledge bank design and maintenance; webinars software and support; needs assessment; monitoring and evaluation framework Training infrastructure Infrastructure: staff; e learning website and knowledge bank design and maintenance; webinars software and support; needs assessment; monitoring and evaluation framework Component 1.1 develop courses and resources including: Online FMD Emergency Preparation Course Real Time Training Modelling as a Decision Support Tool New course possible: Vaccination issues Simulation exercise design Risk Based Surveillance Pillar I Pillar II Pillar III Other Pillar I components: Experience and materials, for example from Balkans or Thrace programmes Other Pillar II components: Experience and materials, for example from Turkey or Egypt projects Re use Pillar I and develop Pillar II courses and resources PCP FMD e learning resources developed and evaluated following needs assessment Delivery costs met by pillar II components Re use Pillar I and II resources for a global audiencewith partners Staff Adminstrative staff team trained to manage adminstration of e learning site and additional position funded by Australian project and MS training contributions Short Term Professional (Magdalena Gajdzinska) to assist 1.1 Externally funded projects eg Australian RTT Externally funded projects eg US DOS in Egypt Training infrastructure Infrastructure: staff; e learning website and knowledge bank design and maintenance; webinars software and support; needs assessment; monitoring and evaluation framework Training infrastructure Infrastructure: staff; e learning website and knowledge bank design and maintenance; webinars software and support; needs assessment; monitoring and evaluation framework Technical resources E learning site upgrade Upgrade appearance Self registration of users Short Open Access Online Courses Technical resources Webinars Up to 2 per week Links to recordings and access from front page e learning site, ability to search recordings, link to certification to explore in future. Ensure monitoring and evaluation 49

52 Training infrastructure Infrastructure: staff; e learning website and knowledge bank design and maintenance; webinars software and support; needs assessment; monitoring and evaluation framework Technical resources Knowledge Bank Support to national cascade of FMD training National training programmes carried out by Member States Yes No Do you organise in-country FMD related training? Better than Google searchable library of training resources (EuFMD and external), job aids and tools Some delay due to funding constraints identification of partners now in progress Do you have training materials or other resource which could be shared ExCom91 Support to national cascade of FMD training Support to national cascade of FMD training Two pilot projects Germany Fully funded by Germany 22 participants Pre/post workshop in Germany, RTT in Kenya Strong emphasis on cascade training Italy 2 3 level cascade approx 20 per course Support provided to development of training concept and specific materials designed to be of use to all MS Two pilot projects Germany Fully funded by Germany 22 participants Pre/post workshop in Germany, RTT in Kenya Materials developed in these two courses will Strong emphasis on be cascade used to training develop a training toolbox to enable other MS to run in country FMD training Italy 2 3 level cascade approx Experiences 20 will course be fed back to MS via training Support provided to focal development points webinar of training concept and specific materials designed to be of use to all MS ExCom91 ExCom91 50

53 Needs based training Needs based training 91 ExCom Hague, 9 10 March ExCom Hague, 9 10 March 2016 Needs Assessment Process Encourage strategic selection of training courses by asking MS focal points to consider: Needs Assessment Process Encourage strategic selection of training courses by asking MS focal points to consider: 91 ExCom Hague, 9 10 March ExCom Hague, 9 10 March

54 Needs Assessment Process Encourage strategic selection of training courses by asking MS focal points to consider: Needs Assessment Process Encourage strategic selection of training courses by asking MS focal points to consider: 91 ExCom Hague, 9 10 March ExCom Hague, 9 10 March

55 53

56 1 Needs Assessment Process: Pillar II Aim to identify common gaps and needs for training across neighbourhood countries. 18 participants required for workshop Priority subject areas? Relation to needs assessment Similar to Pillar I except: Competancies relating to PCP FMD progress No course selection element (EuFMD decides courses to be developed rather than countries themselves Basis for further discussionparticipatory Sent to 24 neighbourhood countries. Assistance from OIE for W Eurasia distribution, follow up at Roadmap Pillar III Short term professional recently recruited (Obakeng Kemolathle Botswana) to assist training and other activities under pillar III. More details from Chris. Recap: question for the Executive FMD Vaccination Where are the biggest gaps in our support to MS and how could they be addressed (training, research priority, vaccination network) 1) Antigen selection and vaccine bank issues 2) Decision making on whether to vaccinate, implications of OIE code change, exit strategies to vaccination 3) Practical planning on how to implement vaccination 54

57 Contingency Planning 91 th Executive Committee meeting of the EuFMD Item: Component 1.2 Improved Contingency Planning Author: Marius Masiulis EuFMD Work Programme Networking (including virtually), improving two way communication Efficient use of limited resources Providing tools 91 ExCom The Hague Netherlands 9 10 March 2016 ExCom91 EuFMD Component 1.2: support contingency planning and develop decision support tools Modeling network Contingency planning network EuFMD Vaccine network (planned) Contingency planning network: a framework for exploring issues such as: business continuity planning; diagnostic bank; Sharing critical human resources. Webpage and discussion forum Webinar series Model Inventory Project (TBD) Guidelines for simulation exercises Knowledge bank Webinar series Advisory group Decision support tools FMD Impact Calculator Vaccine bank antigen decision support tool Promote discussion on vaccine banks and policy issues of vaccine use Training material Modelling network: a framework for modelers to present their work and explore opportunities for collaboration within the EU and globally; Vaccine discussion network a framework for discussing issues such as vaccine bank coordination, post vaccination serosurveillance, policy and contingency planning, and the risk basis for antigen selection. ExCom91 55

58 Webinar series Participants members of: Component 1.2; Component 1.3; Component 1.4; Component 2.1; All interested (Central, local veterinary authority, veterinary practitioners, animal keepers, farmer associations ) Language English and Russian. ExCom91 Webinar series Introductory part Introduction to: strategy of EuFMD, EU, OIE, FAO for control of FMD and legal framework, introduction to PCP; RBSP overview, structure, importance, examples; Contingency plans overview, structure, importance, examples; PCPinWestEurasia anoverview; ExCom91 Webinar series Main part 1 st Part: Economic impact due to animal diseases (e. g. FMD, LSD, ASF); Risk based surveillance plan development and implementation based on Georgia experience; Risk based animal disease surveillance. ExCom91 2 nd Part: Measures in case of animal contagious disease confirmation; Recent outbreak experience combating animal diseases (experience of Balkans, West Eurasia countries); Measures in emergency practical approaches for measures in slaughterhouses, at border inspection post, measures in protection and surveillance zones, movement control; ExCom91 56

59 3 rd Part: Vaccination strategies in emergency & preventive; Epidemiological investigation (example of FMD or other transboundary disease); 5 th Part: Biosafety & biosecurity at all levels within surveillance and eradication of animal diseases including sampling procedure, packing, transportation of samples; 4 Part: Laboratory practical advises. Early warning systems, crisis management and crisis communication ExCom91 ExCom91 Support to sharing critical human resources: Database of experts NATIONAL EXPERTS ON CONTINGENCY PLANS OPERATIONAL MANUALS AND REAL TIME ALERT EXERCISES No. Country Expert's Surname Expert's Name Participation in Expert in the field of* (please, last animal Expert in the animal disease write the most corresponding disease outbreak control/eradication (please Years of expertise field of expertise number of (please write write the animal disease): from 1 to 3): the animal disease): Current work position * means, that expert in the field of: 1. Operational manual (including emergency vaccination) part (practical knowledge of outbreak eradication) measures in case of confirmation, killing / culling of animals, destruction of carcasses by burial, burning or safe delivering to the rendering plant, cleansing and disinfection, additional measures (special cases) applied in slaughterhouses, border inspection post, means of transportation, measures in protection and surveillance zones; 2. Epidemiological inquiry (including counting of the length of time during which the foot and mouth disease may have been present on a holding before being suspected or notified and working ability with tracing of movement of animals, persons, vehicles); 3. Training (real time alert exercises, simulation exercises) part. If your field of expertise cover more than one part of CP, please write the numbers in the order of importance e.g. 1, 3, 2. Countries replayed (out of 38 EuFMD Member States 25 (66 %): Bosnia Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Finland, Georgia, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Norway, Poland, Romania, Serbia, Slovak Republic, Spain, Sweden, Switzerland, The Netherlands, United Kingdom ExCom91 Modeling Network Since initiated in late 2014, it has been growing and now has 121 registered members 2 webinars held since last Executive committee meeting: Dec 2015: Optimising FMD control: the role of clear objectives and real time updating (Will Probert, UK) Jan 2016: Effectiveness and cost efficiency of surveillance for proving freedom & early detection of an emerging disease (Sarah Welby, Belgium) Subgroup of modeling network has submitted a proposal to Horizon 2020 which would include development of a pan European disease spread model FAO/EuFMD is a partner in this proposal 57

60 THRACE Economic impact calculator Tool for rapid assessment of FMD impact Economic and social impact included (quantitative and qualitative) Spreadsheet model Prototype developed by RVC (Jonathan Rushton lead) demonstrated at EuFMD General Session 2015 Next steps: Feedback from target users, validation and refinement of the tool Adapt tool to use output from disease spread model Questions: how much of a priority for next stage development? Should this tool be broadened to include common animal movement modelling tools (Crobodimo request)? Item: Component 1.3 Thrace Item: Component 1.4 Balkans ExCom91 Activities carried out Skype/online Meetings/ conversations; Two Management Meetings (November 2015 and February 2016); The New Database developed for early warning surveillance data Google Fusion: Allows instant mapping; Web based; Free; Three different databases for three countries confidentiality. Operational manual developed and distributed to the countries related; Operational manual translated into Bulgarian (5 consultants working); Consultants were trained via Skype and personally; Cycle reports produced for 3 rd and 4 th quarters 2016; All Thrace countries together with Component 1.4 member countries participated in Wildlife Surveillance Workshop. ExCom91 ExCom91 58

61 Confidence of disease freedom Bulgaria (4 th Cycle) Greece (4 th Cycle) Turkey (4 th Cycle) ExCom91 ExCom91 Order from IZSLER to initiate procurement Import permits and Letters of Acceptance Develop panels Analysis and producing report Acquire and compile results Send parcels and kits ExCom91 ExCom91 59

62 Gap analysis for the region and each particular country Online meeting with all countries discussion of report and issues Online meetings with each country encountered issues Balkans - Management meeting and workshop "Disease confirmation - actions in the outbreak" with presentation of LabEx results Development of roadmap to fill all of the gaps found Discussion of particular country gaps ExCom91 ExCom91 Further actions Contingency Plans & Operational Manuals (CP) to collect for analysis; Laboratory Standard Operational Procedures to collect; Gap Analysis; Reinforcement of the National Legislation; Possible harmonization with EU Legislation; CP testing through Simulation Exercises Thank you very much for your attention! ExCom91 ExCom91 60

63 WRL Submissions to Pirbright January 2015 March 2016 Global Update EuFMD Exec. Committee Donald King WRLFMD Team: Valerie Mioulet, Nick Knowles, Anna Ludi, Ginette Wilsden, Bryony Armson, Pip Hamblin, Kasia Bachanek-Bankowska, Lissie Hendry, Jemma Wadsworth, Britta Wood, Barsha Thapa, Bob Statham, Abid Bin-Tarif, Ashley Gray, Clare Browning, Beth Johns, Mark Henstock, Alison Morris, David Paton, Nick Lyons, Dexter Wiseman, Julie Maryan, Sarah Belgrave FMD Reference Laboratory Additional sequence exchange with Egypt, Russia, India and BVI Reports for these samples can be found at: Recent submissions to WRLFMD Pirbright Since last EuFMD Exec. Comm. (Monza, Sept 2015) FMD: Conjectured global status Seven FMDV serotypes Seven endemic pools requiring tailored diagnostics and vaccines Reports for: Armenia, Botswana, Cambodia, Hong Kong SAR, Iran, Kuwait, Laos, Morocco, Mozambique, Myanmar, Namibia, Niger, Palestinian Aut. Terr., Saudi Arabia, South Korea, Tanzania, Thailand, Turkey, UAE, Uganda, Vietnam, Zimbabwe (22 countries) Results pending for: Israel, Ethiopia, Nepal, Pakistan, Sudan Arranging shipments: Nigeria, Laos No FMD outbreaks in South America (almost 4 years) No outbreaks due to serotype C (~10 years) New FMD free zone (without vaccination) established in northern Kazakhstan 61

64 Coordinating Global Networks OIE/FAO FMD Laboratory Network OIE and FAO Reference Centres (+ affiliates) Working Groups (nomenclature and PVM) Recommendations for Serotype C Global surveillance and changing patterns in risk pathways Harmonised and improved lab capacity Viruses on the move: Changing epidemiological patterns and examples of data sharing between OIE and FAO FMD Reference Laboratories O: North Africa & Middle East Brussels, Belgium November 2015 Outbreaks reported to the OIE (change of epidemiological status): prod/public.php?page=home Recent serotype O cases O/ME SA/Ind2001 lineage from the Indian sub continent Since 2013: FMD Outbreaks in Saudi Arabia, UAE, Bahrain, Libya, Tunisia, Algeria and Morocco (November 2015) Transmission links unknown? 88 O/ALG/1/2014 Increasing threats to Europe 2015 Knowles et al., (2015) TED OIE WAHID O/ /Algeria/2014 (IZSLER) O/TUN/1031/2014* O/TUN/1/ O/1636/Algeria/2014 (IZSLER) O/1631-FA002/Algeria/2014 (IZSLER) O/1631-FA001/Algeria/2014 (IZSLER) O/ALG/3/2014 O/ALG/2/2014 O/TUN/2/2014 O/TUN/1054/2014* O/MOR/1/2015 O/MOR/2/2015 O/MOR/3/2015 O/LIB/12/2013 (KM921837) O/LIB/11/2013 (KM921836) O/LIB/7/2013 (KM921835) O/LIB/22/2013 (KM921841) O/LIB/3/2013 (KM921831) O/LIB/6/2013 (KM921834) 97 O/LIB/2/2013 (KM921830) O/LIB/1/2013 (KM921829) O/LIB/4/2013 (KM921832) O/LIB/13/2013 (KM921838) O/LIB/5/2013 (KM921833) O/LIB/17/2013 (KM921840) O/LIB/16/2013 (KM921839) Vaccine matching for O/ME SA/Ind field isolates: Vaccine strain Field Isolate O-3039 O Manisa O/TUR/5/09 Using VNT r value 0.3 cut off Matched Not Matched LIB 1/2013 LIB 7/2013 LIB 17/2013 LIB 22/2013 NEP 13/2012 NEP 6/2012 NEP 21/2012 NEP 6/2013 NEP 18/2013 NEP 1/2014 NEP 6/2014 SAU 1/2013 SAU 4/2013 SAU 6/2013 SAU 7/2013 SAU 1/2014 SRL 1/2013 SRL 1/2014 UAE 1/2014 UAE 2/2014 ALG 1/2014 TUN 1/2014 BAR 8/2015 BAR 14/2015 MOR/1/2015 MOR/2/2015 borderline borderline borderline borderline borderline borderline borderline borderline 62

65 O/ME SA/Ind 2001 in SEA O/ME SA/Ind2001 lineage from the Indian sub continent Spread to Laos PDR Samples collected in June 2015 Genetically distinct to outbreaks in the Gulf States and North Africa Links to the Indian sub continent not yet defined (imports of frozen tongues from India?) O/NEP/15/2013 (KM921857) O/NEP/18/2013 (KM921860) O/NEP/9/2014 (KM921868) O/NEP/7/2014 (KM921866) O/NEP/8/2014 (KM921867) O/NEP/4/2014 (KM921863) O/NEP/5/2014 (KM921864) O/UAE/1/2014 (KM921877) O/UAE/2/2014 (KM921878) O/BAR/5/2015 O/BAR/2/2015 O/BAR/8/2015 O/BAR/12/2015 O/BAR/3/2015 O/BAR/4/2015 O/IND189/2013* (KM264361) O/IND222/2013* (KM264364) O/NEP/6/2013 (KM921854) O/SRL/1/2013 O/SRL/2/2013 O/IND205/2013* (KM264362) O/NEP/1/2014 (KM921861) O/NEP/2/2014 (KM921862) O/NEP/3/2013 (KM921853) O/NEP/6/2014 (KM921865) O/IND219/2013* (KM264363) O/NEP/11/2013 (KM921855) O/NEP/12/2013 (KM921856) d O/SRL/6/2014 O/SRL/17/2014 Ind-2001 O/SRL/5/2014 O/SRL/1/2014 O/SRL/9/2014 O/SRL/3/2014 O/SRL/15/2014 O/SRL/31/2014 O/SRL/32/2014 O/SRL/30/2014 O/SRL/29/2014 O/SRL/16/2014 O/SRL/7/2014 O/SRL/8/2014 O/SRL/28/2014 O/ME SA/Ind 2001 New full genome analysis Morocco (GenBank: KU291242) Complete genome analysis 47 complete genomes 37 new sequences Iran (2009) UAE(2014) North Africa UAE(2015) Tunisia Algeria 2014 Libya 2013 Morocco Saudi Arabia (2013) Bahrain (2015x2) Laos (2015) O/SRL/34/2014 O/BAR/13/2015 RRLSEA: Pakchong O/BAR/14/2015 O/BAR/15/2015 O/LAO/5/2015 O/LAO/2/2015 O/LAO/3/2015 O/LAO/4/2015 O/LIB/1/2013 (KM921829) O/MOR/1/2015 O/ALG/1/2014 O/TUN/1/2014 O/BHU/3/2009 (KM921814) Multiple escapes from the Indian sub continent Sri Lanka Viruses on the move: Changing epidemiological patterns O North Africa & Middle East SAT 2 and A West EurAsia Outbreaks reported to the OIE (change of epidemiological status): prod/public.php?page=home New serotype A outbreaks in West EurAsia Initial reports September 2015 Saudi Arabia, Turkey, Iran, Armenia Originating from the Indian sub continent A further example of new unexpected FMDV movement between endemic pools Impact upon vaccination? A/SAU/2/2015 A/SAU/6/2015 A/SAU/1/2015 (KU127247) A/SAU/3/2015 A/SAU/4/2015 A/PD78/IND/2015* (PD-FMD) A/SAU/5/2015 A/ARM/2/2015 (ARRIAH) A/IRN/12/2015 A/Van/TUR/203/2015* (FMDI) A/IRN/8/2015 A/ARM/1/2015 (ARRIAH) A/ARM/3/2015 (ARRIAH) A/BAN/GA/Sa-197/2013 (KJ754939) A/IND/256/2012(582)* (PD-FMD) A/IND/84/2011(202)* (PD-FMD) A/IND/113/2012(213)* (PD-FMD) A/IND/413/2007* (HQ127707) A/IND/417/2007* (HQ127708) A/IND/360/2007* (HQ127705) A/IND/245/2007* (HQ832590) A/IND/360/07* (FJ617243) A/IND/245/2007* (HQ127704) A/IND/9/2009* (2008) (HQ127716) A/IND/17/2009* (2008) (HQ127719) A/IND/11/2009* (2008) (HQ127717) A/IND/17/2009* (HQ832592) A/IND/64/2004* (HQ127678) A/IND/64/2004* (HQ832581) A/BHU/4/2003 A/BHU/40/2003 A/IND/281/2003* (HQ832579) A/IND/249/2004* (HQ127680) A/IND/249/2004* (HQ832582) A/IND/243/04* (FJ617245) A/IND/818/03* (FJ617249) A/IND/818/2003* (HQ832580) A/IND/161/2003* (HQ832578) A/BHU/27/2003 (FJ755013) A/BHU/42/2003 A/IND/820/03* (FJ617251) A/IND/447/2005* (HQ832583) A/IND/447/2005* (HQ127685) A/BHU/6/2003 A/BHU/7/2003 (FJ755012) A/BHU/41/2002 (EU414525) A/BHU/8/2003 A/BHU/35/2003 A/SAU/16/95 (EU553874) A/IND/40/2000* (19AF390646) A/IND/154/2013(333)* (PD-FMD) G-VII (G-18) 63

66 A/ASIA/G VII (G18) Poor in vitro match to many commercial vaccines Recent r values: A/SAU/1/2015 A/SAU/2/2015 A/IRN/8/2015 A/IRN/12/2015 A-Iran A-Iran nd nd A-Iran nd nd A-Iran nd nd A-Sau-95* A nd nd A-Tur A-May A-Tur nd A-Tur-14 0 nd 0 0 A-IND * 0.26 nd * Multiple BVS tested A/ASIA/G VII (G18) Full genome of A/SAU/2015 (GenBank: KU127247) Deletion in VP3 59 Amino acid differences in known antigenic sites in lineage A/ASIA/G VII, isolates between three farms Reference viruses Field viruses A/ERI/3/98 A22/IRQ/24/64 A/MAY/97 A/IRN/31/2005 A/TUR/4/2006 A/SAU/1/2015 A/SAU/2/2015 A/SAU/3/2015 A/SAU/4/2015 A/SAU/5/2015 A/SAU/6/2015 Site NSPTP QNLNP KPVSP SPVSP SPVSP VNVSP VNVSP VNVSP VNVSP VNVSP VNVSP Site TSVSPRRGDLGALAARV AGGTGRRGDLGPLAARV TPGA-RRGDLGSLAARD TTGNGRRGDLGPLAARV TTGNGRRGDLGSLAARV AASGRTRGDQGQLAARV AASGRTRGDQGQLAARV AASGRARGDTGQLAARV AASGRARGDTGQLAARV AASGRARGDLEQLTARV AASGRTRGDQGQLAARV A/ASIA/G VII (G18) vaccine trial Viruses on the move: Changing epidemiological patterns Monovalent vaccines not currently available from Merial Hexavalent vaccine O 3039, O Manisa, A Iran 05, A Sau 95, Asia 1, SAT 2 PPG format Challenge at 21 dpv with A/IRN/2015 Results expected at the beginning of April Serological and clinical data analysed in context of detailed information obtained from field cases in Saudi Arabia O/A: SAT2: North Africa & Middle East Outbreaks reported to the OIE (change of epidemiological status): prod/public.php?page=home Multiple lineages East Asia 64

67 O/SKR/10/2010 O/SKR/12/2010 (KC438373) O/RUS/Jul 2010 (JQ070329) O/Andong 1/SKR/2010 (NVRQS) O/DRK/31/2011 O/SKR/7/2010 O/SKR/13/2010 O/Paju/SKR/2010 (NVRQS) 88 O/SKR/1/2011 O/SKR/3/ O/CHA/31/2010* (JF792356) O/BY/CHA/2010 (JN8085) O/JPN/1/ O/JPN/MZ1/2010 (AB618503) O/Yeoncheon/SKR/2010 (NVRQS) O/Yangju/SKR/2010 (NVRQS) O/SKR/8/2011 O/HKN/11/2010 O/HKN/12/2010 O/HKN/10/2010 O/HKN/9/2010 (JQ070304) O/HKN/7/2010 (JQ070303) 88 O/HKN/8/2010 O/HKN/13/2010 O/HKN/14/2010 O/HKN/15/2010 O/GZ/CHA/2010 (JN8086) O/MY/CHA/2010 (HQ652079) O/VN/LC169/2009 (HM055510) O/VIT/NCVD-8/2010 (NVRQS) O/VN/YB08/2010 (HQ260718) 90 O/VIT/NCVD-9/2010 (NVRQS) O/VN/YB09/2010 (HQ260719) O/VN/YB10/2010 (HQ260720) O/GSLX/CHA/2010 (JQ900581) O/NC/CHA/2010 (HQ652080) O/HKN/19/2010 (JQ070305) 100 O/HKN/20/2010 (HM229661) O/33-P/CHA/2010 (JQ973889) 72 O/SKR/4/2010 (JQ070320) 81 O/KOR/1/2010* (HM143846) O/GZ-MT/CHA/2013 (KJ646655) 100 O/SKR/6/ O/SKR/01/2014* (APQA) 97 O/Primorskiy/RUS/2014 (ARRIAH) O/SKR/14/2014 O/SKR/16/2014 O/SKR/18/2014 O/JC/CB/ROK (APQA) O/SKR/12/2014 O/SKR/1/2016 O/SKR/2/2016 O/SKR/3/2016 O/SKR/4/2016 O/SKR/5/2016 O/Gimje/KOR/2016* (QIA) O/MYA/7/98 (DQ164925) East Asia: outbreaks due to exotic FMDVs FMD outbreaks since 2008 Spread of three FMD virus lineages from Southeast Asia: O/ME SA/PanAsia China, Russia, Mongolia, Kazakhstan O/SEA/Mya 98 China, Japan, South Korea, North Korea, Russia, Mongolia 2015, Taiwan (China, Japan, RoK A/ASIA/Sea 97 South Korea, China, Kazakhstan, Mongolia, Russia, Taiwan (2015) OIE: WAHID FMD Outbreaks in South Korea December 2014 on going January 2016 Further 4 outbreaks (O/SEA/Mya 98) Sequence data indicates continued circulation of FMD in SKR from 2014 Thai-87 Cam-94 WA EA-1 EA-4 EA-3 EA-2 ME-SA EURO-SA ISA-2 ISA-1 CATHAY Mya-98 SEA Vaccine Bank Recommendations (March 2016) High Priority Medium Priority Low Priority A/ASIA/G-VII(G-18)* O Manisa O PanAsia-2 (or equivalent) O BFS or Campos A24 Cruzeiro Asia 1 Shamir A Iran-05 (or A TUR 06) A22 Iraq SAT 2 Saudi Arabia (or equivalent i.e. SAT 2 Eritrea) A Eritrea SAT 2 Zimbabwe SAT 1 South Africa A Malaysia 97 (or Thai equivalent such as A/Sakolnakorn/97) A Argentina 2001 O Taiwan 97 (pig-adapted strain or Philippine equivalent) A Iran 96 A Iran A Iran 87 or A Saudi Arabia 23/86 (or equivalent) A15 Bangkok related strain A87 Argentina related strain C Noville SAT 2 Kenya SAT 1 Kenya SAT 3 Zimbabwe *Recent in vitro data from WRLFMD for serotype A viruses from Saudi Arabia and Iran highlights an apparent gap in vaccine coverage. Work is urgently required to evaluate whether there is adequate in vitro match with Indian vaccine strains (A/IND/40/2000) or whether in vivo protection may be provided by high potency international vaccines. Current WRLFMD Training Activities Annual Lab diagnosis training course 2 weeks hands on at Pirbright November 2016 E learning modules under development to enhance precourse preparation, for those that cannot attend and for TPI staff training Contribution of materials and trainers to EuFMD courses OIE twinning with National Animal Health and Diagnostic Investigation Centre, Ethiopia Field testing technology validation and transfer 65

68 National Funding Obtained for Upgrading of E Learning Materials Talk summary Epidemiology of FMD is very dynamic Sampling of field outbreaks is critical During 2015 new unpredictable patterns in Asia (East and West) and North Africa Established lineages within serotypes O, A, and Asia 1 Emerging lineages within serotypes O, A, and SAT 2 Threats to FMD free countries in Europe and Turkish Thrace Impact upon selection and deployment of vaccines Multiple FMDV lineages may have different epidemiological features Importance of the sample collection from FMD outbreaks in the field to feed real time lab data back to FMD control programmes Network report: Acknowledgements Contributions and suggestions welcome Support for the WRLFMD and research projects Collaborating FMD Reference Laboratories and field teams Partners within the OIE/FAO FMD Lab Network 66

69 Benefits of vaccine field studies Don King and Nick Lyons Always uncertainty about heterologous vaccine performance A/ASIA/G VII and Asia 1/Sindh 08 Experimental potency tests are often performed Expensive Artificial exposure Limited sample size Field based studies provide real life picture of vaccine performance See: previous projects from Nick Lyons and Theo Knight Jones Possible ideal study criteria/design to maximise impact for the EU Where possible, vaccines (or antigen components) should be equivalent and matched to those in the EU bank(s) Endemic setting where FMDV exposure can be anticipated Similar livestock production systems (and breeds) to Europe Access to farm records (herd and individual animal level) Good veterinary and transport infrastructure Local enthusiasm for the project and benefit for the farmer Data can be used: 1. to optimise vaccine use in endemic settings 2. to contribute to our understanding of vaccine use for emergency settings 67

70 Progressive Control 91 th Executive Committee meeting of the EuFMD Pillar II Item: Pillar II and III Progressive control of FMD in neighbourhood and in support of the Global Strategy Author: Chris Bartels 91 ExCom Hague, 9 10 March ExCom Hague, 9 10 March South East Mediterranean OBJECTIVE: better FMD management in the neighbourhood of Cyprus and Israel OUTPUTS: 1. Risk based Strategy Plans (RBSP) adopted, implemented and monitored in Egypt 2. RBSP adopted, implemented and monitored in Palestine and Israel; 3. RBSPs developed and PCP FMD progress in Jordan and Lebanon; 4. Network for improved disease risk information and exchange: risk based surveillance, risk based vaccination programmes and vaccine selection for the threats from particularly bordering areas in the Middle East and sub SaharanEast Africa 2.2South East Mediterranean OBJECTIVE: better FMD management in the neighbourhoodofcyprusandisrael OUTPUTS: 1. Risk based Strategy Plans (RBSP) adopted, implemented and monitored in Egypt 2. RBSP adopted, implemented and monitored in Palestine and Israel; 3. RBSPs developed and PCP FMD progress in Jordan and Lebanon; 4. Network for improved disease risk information and exchange: risk based surveillance, risk based vaccination programmes and vaccine selection for the threats from particularly bordering areas in the Middle East and sub Saharan East Africa Issues No feasible solution found between LLNL/US DOS and EuFMD/FAO for (sub)contracting the activities, and this has led to significant delays in planning Consultant capacity for carrying out missions/workshops is low. Availability of experienced trainers seems to be a limiting factor. Priorities Starting PCP/RBSP work in Jordan Starting PCP/RBSP work in Lebanon Planning a joint workshop on strategic surveillance and strategic vaccination for Israel and Palestine Integrating webinar/e learning activities for the Near East with similar already started activities under component 2.3 (support to REMESA). 91 ExCom Hague, 9 10 March ExCom Hague, 9 10 March

71 2.4 Training development and coordination Issues The Secretariat has identified opportunities for collaboration with academic institutions in the North Africa and Middle East regions These collaborations (see also under components 2.2 and 2.3) will allow EuFMD to work with universities to deliver online courses in local languages and making use of local expertise Discussion Priorities Collation of results from the training needs assessment Research of existing training courses, in order to define priorities for training development for the next 18 months Drawing up a plan, timescale and budget for new training to be developed and delivered Pillar III 91 ExCom Hague, 9 10 March ExCom Hague, 9 10 March Support to Global progress Monitoring 3.1 Support to Global progress Monitoring Support upon request of FAO/OIE FMD WG International progress monitoring system (3.1.1) and Annual Global FMD report (3.1.2) Global questionnaire developed and sent out EUFMD possibly involved in data analysis Provision of PCP FMD training to experts in the field of FMD (3.1.3) No requests forwarded by FMD-WG In country mission upon request by countries (3.1.4) No requests forwarded by FMD-WG Support upon request of FAO/OIE FMD WG International progress monitoring system (3.1.1) and Annual Global FMD report (3.1.2) Global questionnaire developed and sent out EUFMD possibly involved in data analysis Provision of PCP FMD training to experts in the field of FMD (3.1.3) No requests forwarded In country mission upon request by countries (3.1.4) No requests forwarded Issues for Ex Com Flexibility needed as requests have not yet been forthcoming EuFMD s capacity to train is stretched, however activities under Pillar III (training) are meant to solve Priorities Regular and close contract with FAO/FMD unit and FAO/OIE FMD Working Group Re-addressing targets may be necessary (3.1.1 and 3.1.2) STP Obakeng Kemolathle 91 ExCom Hague, 9 10 March ExCom Hague, 9 10 March

72 3.2 Methods and guidelines for PCP FMD application PCP FMD Toolbox Revision PCP guidelines (fast-track, Stage 5) RBSP guidelines - inclusion of requirement enabling environment Socio-economic guidelines Training of PCP FMD experts Planning training of FAO and OIE regional staff Support to FMD Regional Roadmap meetings Near-East and Northern Africa, Doha, December 2015» Coordination and agreement on R&R regional and global FAO, OIE and EuFMD» Sufficient time for assessment (interview, RAG procedure)» Pre-meeting training on PCP-FMD Upcoming West Eurasia (Bishkent in April) and SAARC 3.2 Methods and guidelines for PCP FMD application PCP FMD Toolbox Revision PCP guidelines (fasttrack, Stage 5) RBSP guidelines - inclusion of requirement enabling environment Socio-economic guidelines Training of PCP FMD experts Planning training of FAO and OIE regional staff Support to FMD Regional Roadmap meetings Near-East and Northern Africa, Doha, December 2015» Coordination and agreement on R&R regional and global FAO, OIE and EuFMD» Sufficient time for assessment (interview, RAG procedure)» Pre-meeting training on PCP-FMD Upcoming West Eurasia (Bishkent in April) and SAARC Issues As with 3.1, dependent on decision making process of FAO/OIE FMD Working Group Priorities Developing Pre-Roadmap meeting training (see 2.4) Training of PCP-FMD experts 91 ExCom Hague, 9 10 March ExCom Hague, 9 10 March Laboratory support 3.3Laboratory support Coordination OIE/FAO FMD Laboratory Network Meeting (Bruxelles, November 2015) Working group on nomenclature Working group on vaccine recommendations for endemic situations Surveillance Detection of serotype A, VII strain Global Monthly Report FASTA funds for pools 4 and 5 Epi surveillance networks EARLN webinar series Global PT scheme 19 laboratories Coordination OIE/FAO FMD Laboratory Network Meeting (Bruxelles, November 2015) Working group on nomenclature Working group on vaccine recommendations for endemic situations Surveillance Detection of serotype A, VII strain Global Monthly Report FASTA funds for pools 4 and 5 Epi surveillance networks EARLN webinar series Global PT scheme 19 laboratories Priorities Annual report on global FMD status Progression in the work of the OIE/FAO laboratory network working groups Training needs assessment pillar III countries Missions to RSLs in pools 4 and 5 (WRLFMD/EuFMD) Development of laboratory e- learning materials Webinar series for East Africa implemented and for West Africa planned 91 ExCom Hague, 9 10 March ExCom Hague, 9 10 March

73 3.4 Global access to PCP FMD training resources PCP and associated training resources tested, evaluated and available for use in African FMD endemic regions Identification of partners in Southern Africa Concept note with FAO sub-regional office for SA Recruitment of STP Obakeng Kemalathle (Botswana) who will support activities across pillar III including: 3.1,3.2,3.3:» Activities in support of FMD WG (inc SADEC roadmap if required)» Activities in support of regional networking - 3.4:» Training needs assessment» Delivering e-learning course» Adaptation of training materials 3.4 Global access to PCP FMD training resources System for sustainable use of PCP training resources in at least two regions outside the European neighbourhood, and supportive to the establishment of regional and global PCP FMD networks of trainers and users Network of PCP practitioners Launch in April/May 2016 concurrently with PCP-FMD e-learning Similar approach in SAARC region later this year 91 ExCom Hague, 9 10 March ExCom Hague, 9 10 March 2016 Practitioners community Key aims Promote and extend global use of PCP Support those using the PCP Informal and formal training How to apply PCP-FMD to my situation? Offer a platform to other users learn from and share experience with others From passive to active users Practitioners make use of what is offered in EuFMD s e-environment and develop/create their own required package Packages are uploaded and shared with other practitioners 91 ExCom Hague, 9 10 March 2016 Levels of PCP FMD users PCP experts- eg EuFMD/OIE/FAO- those who have been through the higher level training courses PCP practitioners- those working in government veterinary services using PCP-FMD, also others such as NGO, non-expert consultants, academics, farm managers who work on FMD disease control PCP beginners- people who want to know more about the PCP but aren t using it yet 91 ExCom Hague, 9 10 March

74 How to join the community? Sign up to take PCP FMD practitioner level and acquire your PCP FMD practitioner community certificate What benefits does the community offer? Guided discussion forum with posts (exercises, examples, job aids) every fortnight Direct links into interesting things in the Knowledge Bank KNOWLEDGE BANK Different levels of PCP FMD participation and the EuFMD e Environment PCP-FMD user country based Involved in FMD control PCP-FMD interested Webinar series On-line meetings PCP-FMD e-learning Access to contact details of community members sharing experiences Reduced fee for PCP-FMD on-line training courses PCP-FMD participant Regional network Involved on FMD control based on position and background (epidemiology, diagnostics, organisational) PCP-FMD practitioner community Applying PCP concept Community member Interest in learning & sharing 91 ExCom Hague, 9 10 March 2016 JOB AIDS 91 ExCom Hague, 9 10 March 2016 TUTORING AND DISCUSSION PCP-FMD EXPERT 3.4 Global access to PCP FMD training resources Discussion points Issues We would appreciate feedback from the Executive Committee in order to understand their level of support for the Secretariat seeking additional financial support for the global extension of EuFMD s training resources discussion Priorities Needs assessment in SADC Pilot regional e Learning course Supporting regional partners to develop their own training hub based on virtual technologies (sustainability) Starting in SAARC region Launching of PCP FMD e Learning and PCP practitioners community Assessing current situation = High demand for training from across the globe versus limited resources with EuFMD, FAO and OIE Routes: Try and train people by a resource-low, do-it-yourself style PCP-FMD e-learning, Knowledge Bank, Job-Aids, webinars Audiences: PCP practitioners, plus field vets, students Partnerships with Universities (2.2 and 2.3) supporting development and delivery of Continued Professional Development (CPD). Advantages of sustainability, practicality, outreach and generation OIE support on CPD and role of Veterinary Statutory Bodies in promoting CPD Funding: additional routes and audiences to be financed by other sources What, who, where 91 ExCom Hague, 9 10 March ExCom Hague, 9 10 March

75 FMD situation/turkey CIRCULATING STRAIN A.Naci BULUT Şap Institute,Ankara,Turkey FMD SITUATION IN TURKEY A ASIA/GVII OUTBREAKS EuFMD 91th Executive Committee Meeting 9 10th March2016, The Hague, The Nederland On behalf of Dr. Nihat Pakdil Deputy Secretary of Ministry The Ministry of Food, Agriculture and Livestock (MoFAL) FMD is endemic in Anatolia region in Turkey Current Circulating virus strains: Serotype O (O PanAsiaII), A (Asia/GVII)* and Asia-1(Asia1/SINDH08) Thrace region has been free of FMD with vaccination since May th Executive Committee Meeting, The Hague, The Nederland, 9 10th March FMD Situation Before New Serotype A, A(ASIAGVII) Incursion (2015, till October) Chronology of New Incursion 29 Sep15 Clinical Detection of FMD; Indexcase Buzhane, Ipekyolu Van Before the new incursion; Occasional outbreaks were recorded in this period of In total: Serotype O, 30 A, 13 Asia1 and 7 PCR (+). With low incidence (<0.3) and ignorable mortality rate. 2 Oct15 9 Oct15 9 Oct15 24 Oct15 10 Nov15 24 Nov15 Lab Diagnosis, serotype A Molecular Analysis Result: A new incursion 9 Oct15 Shifted emergency response Initiated adaptation of a new vaccine strain Finalized 1st step of the adapdation proces Initiated QA and vaccine matching testing Finalized 1st step vacc. Matching test First monovalent vacc. Delivering for emergency vaccination 21,2% distinct fromturkey2015 (AIRN2005) Initiated active clinical surveillance program Leading by expert central level Animal markets were closed in area which detected high risk Movement was banned from/to high risk area and monitoring shifted emergency level Increase awareness activities covering all stakeholders r value was indicated A (AsiaGVII) vaccine strain was matched very well QA tests also finalized for 1st batch vacc. 91th Executive Committee Meeting, The Hague, The Nederland, 9 10th March Dec15 Proponed spring campaign vaccination 91thExecutiveCommittee Meeting The Hague TheNederland 9 10thMarch2016 Tetra valency vaccine (O PanasiaII/, A (AsiaGVII, A Iran05/A Tur14 and 4 Asia1/SINDH08) was used for campaign 73

76 Number of Outbreaks 2013; n ; n ; n (62/513) (2m); n 116 Number of FMD outbreaks occurred by years (2016 till Feb) FMD OUTBREAKS BY YEARS A (ASIAGVII) Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan16 Feb th Executive Committee Meeting, The Hague, The Nederland, 9 10th March Num. Of Outbreaks Supplied Vaccine vs No of Outbreak during new outbreak wave Nov Nov Nov 30 Nov 6 Dec th Executive Committee Meeting, The Hague, The Nederland, 9 10th March Dec Dec Dec 28 Dec Jan Jan Jan Jan Feb Feb Feb Jan16 Timeline Amount ofvaccine(x000 dose) No Outbreaks Map Distribution for Outbreaks in between January October2015 Map Distribution of FMD Outbreaks Occurred in 2016 JAN 2016 Total:83 Serotype O:2 Serotype A:76 PCR(+) : 5 Map Distribution for Outbreaks due to A/ AsiaGVII Nov /Dec 2015 FEB 2016 Total:33 Serotype O:1 Serotype A:32 91th Executive Committee Meeting, The Hague, The Nederland, 9 10th March th Executive Committee Meeting, The Hague, The Nederland, 9 10th March

77 FMD Situation In the regions_we and SEA 91th Executive Committee Meeting, The Hague, The Nederland, 9 10th March2016 By Dr. King, from EuFMD Webinar Representative phylogenetic trees: O O/IRN/8/ O/IRN/6/ O/PAK/14/ O/AFG/34/2007 O/NEP/4/ O/PAK/1/ OAPV9304/2004 O/Tunceli/932/2012 O/IRN/2/ O/Erzincan/594/2010 ANT O/Gaziantep/153/ O/BUL/1/2010/2011 O/KAZ/Korday/JQ765585/ O/Ardahan/57/2015 O/Eskisehir/109/2015 FAR-09? O/GAntep/172/ O/Bitlis/75/ O/Tunceli/169/ O/Nigde/49/ O/Agri/63/ O/Samsun/129/2010 FAR-09 O/Agri/72/ O/Adana/57/ O/Eskisehir/205/ O/Gumushane/1237/2012 O/BAG/AFG/L1494/2009 O/KMaras/1127/ O/BHU/1/18 75 O/UKG/3/2001 O/BAN/NA/Ha-156/2013 O/IND2/ O/BHU/1/ O/LIB/2/ O/SAU/3/2013 O1/BFS1860/UK/1967 O2/Brescia/ITL/1947 O2/Flanders/BEL/1947 O1/Manisa/TUR/ th Executive Committee Meeting, The Hague, The Nederland, 9 10th March IND-2001 PanAsiaII PanAsiaI Representative phylogenetic trees: A (ASIAGVII) 0.02 IND A/BAN GA Sa /2014 A/BAN CH Ra14/2012 A/SAU/1/2015 A/Van/203/2015 A/Bitlis/205/ A/Van/175/ A/Van/198/ A/IND1/2010 A/IND898/2009 A/PD135/ A/IND249/ A/IND64/2004 A/IND161/ A/BHU/27/ A/BHU/41/ A/BHU/7/ A/SAU/16/95 A/IND/256/98 A/ALB/1/16 A/IND/287/16 53 A/IND/270/16 31 A/IND/84/17 IND A/SAU/23/86 A/ASIAGVII A/IRN/1/16 A22 A15/Bangkok/TAI/1960 A12/UK/119/1932 A24/Cruzeiro/BRA/1955 A11/GER/1929 A/IRN/2/ A/TAI/7/2003 A/IRN/32/ A05 A23/Kitale/KEN/1964 A Representative phylogenetic trees: A (A05 SIS 10 ) GVII A/IRN/1/16 A22/Iraq/1964 A22 A22/Mahmatli/1964 A15/Bangkok/TAI/1960 A12/UK/119/1932 A24/Cruzeiro/BRA/1955 A11/GER/1929 A/IRN/2/ A/TAI/7/2003 GVII 89 A/IRN/32/ Former isolates A/Eskisehir/174/2015 A/Kocaeli/180/2015 A/Cankiri/346/ A/Kirsehir/154/2015 A/Erzurum/168/2015 A/Van/327/ A/Denizli/1538/ A/Agri/902/ A/Cankiri/1/2014 Strains Distance 83 A/Balikesir/79/ A/Kayseri/78/2014 Saudi2015 1,3% A/Kastamonu/315/2014 Bangaldesh2013 4,7% 97 A/Amasya/340/ A/Iraq/Babil/A218/2012 Albania96 10,5% A/Bingol/184/ Saudi95 10,8% A/Bingol/1062/ A/Malatya/37/2013 NEP 84 14,0% 93 A/Van/1204/2012 AIRN96 17,3% 89 A/Kars/729/2013 A23/Kitale/KEN/1964 A22/Mahmatli/ ,3% 43 A/IRN/22/19 A AIRN87 19,0% A/Kirsehir/124/2004 Turkey2015 (AIRN2005) 21,2% 0.02 AIRN 21,4% AIRN2005 (index) 22,2% SIS-10 A05 11 Representative phylogenetic trees: Asia Asia1TUR2011 Asia1/Slemani/IRQ/2012 Asia1/Ankara/1253/2012 Asia1/Erzincan/872/2012 Asia1/Kars/74/2013 Asia1/PAK/109/2010 Asia1/Duzce/945/2011 Asia1/Adana/18/ Asia1/Elazig/10/2015 Asia1/Kocaeli/113/2015 Asia1/Eskisehir/118/ Asia1/Igdir/112/2015 ASIA1/PAK/26/2009 As/SIN/PAK/L2810/2009 Asia1/Balikesir/94/2013 Asia1/Ardahan/334/2014 Asia1/Ankara/345/2014 Asia1/Kars/60/2015 As1/AFG/1/2001 As1/HKN/19/1974 As1/Asia-1/PAK/ Sindh As1/IND/18/1980 As1/TAI/1/98 As1/Shamir/ISR/ As1/BHU/27/2002 As1/IND As1/IND/14/15 25 Asia1/Kayseri/121/ As1/MYA/2/2001 Asia1/CIN/GUIZHOU/ As1/PAK/30/ As/BAM/AFG/L2824/ th Executive Committee Meeting, The Hague, The Nederland, 9 10th March

78 LATEST FMD SITUATION AND CONTROL POLICY Although the new outbreak wave, due to A (Asia/GVII), was spread pandemic in the beginning, there has been recorded declining number of outbreaks at the moment as a result of strict control measures. Spring 2016 vaccination campaign has been proponed to December 2015 (December th March). The Campaign has been mainly included LR vaccination. However, SR has been also included in some area in which it has been identified high risk. More than 15.5 million tetra valence (included one batch monovalent) vaccine has been delivered for campaign vaccination targeting with at least 90% coverage. Till now, 93% vaccination coverage was achieved (still continued). Booster vaccination has been also implemented for primo vaccinator cattle in Marmara (included Thrace region) and Aegean regions. Vaccination campaign in Marmara and Aegean will be implemented 3 times in Emergency vaccination response to outbreak has been implemented regularly including SR. Clinical surveillance and outbreak case studies have been continued. Movement and animal market control measures has been strictly monitored. Markets and movements have been banned in the area in which it was identified high risk. Poster and leaflet have been prepared and delivered for enhance awareness It has been planned additional vaccination campaign in Marmara and Aegean regions on May CONTROL POLICY CONDUCTED IN THRACE REGION All control measures compliance with Terrestrial Manuel of OIE in order to keep confidence of disease free status with vaccination. Thrace Risk Based Surveillance Program (Thrace RBSP) support by EuFMD has been conducted successfully. In addition to Thrace RBSP, clinical surveillance has been conducted three times by central epidemiology teams since detected new A virus incursion so that it can be keep confidence of the freedom 91th Executive Committee Meeting, The Hague, The Nederland, 9 10th March th Executive Committee Meeting, The Hague, The Nederland, 9 10th March Thank you very much for your attention! Acknowledges Fuat Ozyörük Unal Parlak Dr.King, The Pirbright Institute The Şap Institute General Directorate for Food and Control (GDFC) 15 76

79 Russian Proposal Russian Proposal st Session of the EuFMD Executive Committee Risks of FMD introduction in Western Eurasia FMD Type A outbreaks were originally reported in September 2015 in Saudi Arabia, in November in Turkey and Iran and in January 2016 in Armenia. The virus originates from the Indian subcontinent and belongs to G VII genetic lineage An example of a novel unexpected FMD introduction from other ecological pool The Hague, Netherlands 9-10 March 2016 Proposals of the Russian Federation Dr Nikita Lebedev Федеральная служба по ветеринарному и фитосанитарному надзору (Россельхознадзор) Федеральная служба по ветеринарному и фитосанитарному надзору (Россельхознадзор) 2 A/SAU/2/2015 A/SAU/6/2015 A/SAU/1/2015 (KU127247) A/SAU/3/2015 A/SAU/4/2015 A/PD78/IND/2015* (PD-FMD) A/SAU/5/2015 A/ARM/2/2015 (ARRIAH) A/IRN/12/2015 A/Van/TUR/203/2015* (FMDI) A/IRN/8/2015 A/ARM/1/2015 (ARRIAH) A/ARM/3/2015 (ARRIAH) A/SAU/2/2015 A/SAU/6/2015 A/SAU/1/2015 (KU127247) A/SAU/3/2015 A/SAU/4/2015 A/PD78/IND/2015* (PD-FMD) A/SAU/5/2015 A/ARM/2/2015 (ARRIAH) A/IRN/12/2015 A/Van/TUR/203/2015* (FMDI) A/IRN/8/2015 A/ARM/1/2015 (ARRIAH) A/ARM/3/2015 (ARRIAH) A/BAN/GA/Sa-197/2013 (KJ754939) A/IND/256/2012(582)* (PD-FMD) A/IND/84/2011(202)* (PD-FMD) A/IND/113/2012(213)* (PD-FMD) A/IND/413/2007* (HQ127707) A/IND/417/2007* (HQ127708) A/IND/360/2007* (HQ127705) A/IND/245/2007* (HQ832590) A/IND/360/07* (FJ617243) A/IND/245/2007* (HQ127704) A/IND/9/2009* (2008) (HQ127716) A/IND/17/2009* (2008) (HQ127719) A/IND/11/2009* (2008) (HQ127717) A/IND/17/2009* (HQ832592) A/IND/64/2004* (HQ127678) A/IND/64/2004* (HQ832581) A/BHU/4/2003 A/BHU/40/2003 A/IND/281/2003* (HQ832579) A/IND/249/2004* (HQ127680) A/IND/249/2004* (HQ832582) A/IND/243/04* (FJ617245) A/IND/818/03* (FJ617249) A/IND/818/2003* (HQ832580) A/IND/161/2003* (HQ832578) A/BHU/27/2003 (FJ755013) A/BHU/42/2003 A/IND/820/03* (FJ617251) A/IND/447/2005* (HQ832583) A/IND/447/2005* (HQ127685) A/BHU/6/2003 A/BHU/7/2003 (FJ755012) A/BHU/41/2002 (EU414525) A/BHU/8/2003 A/BHU/35/2003 G-VII (G-18) Antigenic relationship (r 1 ) between А/ASIA/G-VII strain and production strains using NT Production strains А 22 /Iraq/64 А /Iran/97 А /Turkey/06 (А/Iran/05) А/Zabaikalsky/ 2013 (А/Asia/SEA-97) А/Krasnodarsky/ 2013 (А/Iran/05/SIS 10) А/ASIA/G-VII N N N N N М vaccine strain protects from FMDV field isolate N the vaccine strain shall be substituted as this strain does not protect from the FMDV field isolate Results of tests for determination of antigenic relationship (r 1 ), performed in the FGBI ARRIAH, demonstrated that applied FMD vaccines containing antigens (A 22 IRQ; A Iran 2005; A TUR 20/06; А/Asia/SEA-97 and А/Iran/05/SIS 10) don t protect animals from FMDV type A, G-VII genetic lineage. A/SAU/16/95 (EU553874) A/IND/40/2000* (19AF390646) Федеральная служба по ветеринарному и фитосанитарному надзору (Россельхознадзор) A/IND/154/2013(333)* (PD-FMD) 3 Федеральная служба по ветеринарному и фитосанитарному надзору (Россельхознадзор)

80 Федеральная служба по ветеринарному и фитосанитарному надзору (Россельхознадзор) 5 Федеральная служба по ветеринарному и фитосанитарному надзору (Россельхознадзор) 6 Countries involved (n=6): Countries: Republic of Georgia, Republic of Armenia, Republic of Azerbaijan, The Republic of Turkey(provinces: Artvin, Ardahan, Kars, Iğdır, Ağrı), The Islamic Republic of Iran (ostani: West Azerbaijan, East. Azerbaijan, Ardebīl, Gilan), The Russian Federation (the Krasnodar Krai, the Karachayevo-Cherkessian Republic, the Kabardino-Balkarian Republic, the Republic of North Ossetia, the Republic of Ingushetia, the Republic of Chechnya, the Republic of Dagestan, Adygeya). Goals Goal Implementing steps of the Progressive Control Pathway for FMD (EU FMD/OIE/FAO) in the Caucasian region : Implement the second step of the Progressive Control Pathway for FMD ( road map EU FMD/OIE/FAO) in Georgia, Armenia and Azerbaijan; Implement the first step of the Progressive Control Pathway for FMD ( road map EU FMD/OIE/FAO) in Abkhazia, South Ossetia and Nagorny Karabakh; Implement the third and following steps of the Progressive Control Pathway for FMD ( road map EU FMD/OIE/FAO) in countries/territories involved into the Draft Programme on FMD Surveillance (hereinafter the Draft); Ensure effective buffer protection from FMD introduction into/out of the region and into the EU and RF territory; Федеральная служба по ветеринарному и фитосанитарному надзору (Россельхознадзор) 7 Федеральная служба по ветеринарному и фитосанитарному надзору (Россельхознадзор)

81 Objectives 1. Implementation of the pilot program to determine the local Veterinary Services needs and readiness to prevent FMD. 2. Development of an effective/progressive FMD control (based on the risk analysis)/surveillance program in the Caucasian region 3. Coordination of FMD activities carried out by the Member States including establishment of a system of communication about the epidemic situation and the surveillance results 4. Establishment of an effective buffer zone for FMDV introduction prevention using uniform FMD vaccine comprising the vaccine strains most relevant for a given region 5. Introduction of a surveillance system (both active and passive), including monitoring investigations and disease outbreak investigations 6. Scientific and technical cooperation in the following areas: training of staff members (diagnosis, epidemiology, clinical diagnosis, etc.), risk assessment, epidemiology, also in regards to susceptible wild animals. Expected Results Functioning of the framework program on the Caucasian Veterinary Services coordination for FMD control. Implementation of the stages of the FMD Progressive Control Pathway (EU FMD/OIE/FAO) - supporting National Veterinary Services and Diagnostic Centers in implementation of national programs on prevention of FMD and other transboundary animal diseases - serum bank establishment and maintenance, replenishment of the collection of currently important FMD isolates; Федеральная служба по ветеринарному и фитосанитарному надзору (Россельхознадзор) 9 Федеральная служба по ветеринарному и фитосанитарному надзору (Россельхознадзор) 10 Expected results - development and implementation of the training programs for all stakeholders including private and official veterinarians, technicians, farmers, heads of relevant central and local institutions, slaughterhouse managers, laboratory personnel and inspectors of border inspection posts on the following aspects: foot-and-mouth disease, epidemiology, transmission routes, persistence; procedure for the disease outbreak investigation; sample collection, preparation and transportation; principles of the disease control, quarantine, movement limitations; biosecurity, cleaning and disinfection, safe disposal; vaccines, vaccination and immunity. As a result of the program implementation consistent FMD freedom of the countries is expected followed by the OIE recognition as FMD free countries where vaccination is practiced (4th and 5th PCP stages). Thank you for your attention! Федеральная служба по ветеринарному и фитосанитарному надзору (Россельхознадзор) 11 Федеральная служба по ветеринарному и фитосанитарному надзору (Россельхознадзор)

82 Remesa Support to REMESA Component 2.3 TUNISIA ALGERIA 143 outbreaks from 25/04/2014 to 13/10/ outbreaks from 23/07/2015 to 22/09/ outbreaks from 2/3/2015 to 11/04/2015 MOROCCO 6 outbreaks from to Programme developed on the basis of previous activities and assessments E.g. Important assessment held during the workshop: PURPOSE OF THE WORKSHOP The purpose of the workshop is to reach a common understanding on the difficulties associated with the control of the FMD in , and to identify from Lessons learnt the priorities for attention for a REMESA Regional Strategy. Recommendations 1/2 IMPROVEMENTS on PREVENTION Animal movement control and mapping >Passive surveillance collaboration with stakeholders >Risk based surveillance >Regional surveillance strategy Regional Reference laboratory STRENGTHENING of FMD CONTROL Animal movement control during outbreaks Biosecurity measures and equipment >Sanitary measures in outbreaks Cost benefit analysis Vaccine/antingen bank >Vaccination preparedness In italics the items included in the EuFMD workplan 80

83 Recommendations 2/2 IMPROVING MOBILIZATION of HUMAN and FINANCIAL RESOURCES Cost benefit analysis Harmonization of regulatory framework Structure of veterinary Services Regional animal disease funds STRENGTHENING of COMMUNICATION >Coordination among partners >Opportunity and tools to exchange information >Awareness during peace time Workplan The workplan is focused on improvement in short and long term management of the national FMD risk, with tangible indicators of progression along the PCP Pathway, towards OIE recognition of FMD freedom and a regional strategy for FMD control. The programme is based on the support to: develop, adopt and implement Risk Based Strategic Plans for FMD control in Libya and Mauritania, and the capacity to achieve and maintain PCP stage 3 or 4 in Morocco, Algeria, Tunisia; implement a coordination framework in order to facilitate communication, review and guide upon activity implementation at national and regional level, create a system to improve availability of disease risk information for planning of surveillance, control and vaccination programmes, and developing vaccine banks. All the activities and the related outcomes can help to provide information to support analysis of risk of FMD incursions into the European neighbourhood. In italics the items included in the EuFMD workplan Workplan Planned activities Epi and Lab network Early warning risk based surveillance Emergency preparedness Vaccination programmes Self assessment tool Risk Based Strategic Plan Status of the activities Outcome 1: Progress on FMD control A workshop is being held in Rabat, Morocco, on the 7 9 March 2016 on Foot and Mouth Disease early detection and freedom confidence Nr. 7 Ag detection ELISA Kits have been delivered to Morocco and they will be distributed to the 6 regional laboratories and to the central laboratory of ONSSA, (under 1.6 component) 2016 elisa kits have been delivered to Algeria to support the serosurveillance planned for the end 2015/beginning 2016 to give evidence to the absence of FMDV circulation and for the assessment of vaccine effectiveness A training on virus isolation has been held in ANSES on the 7 11 March 2016 as part of the laboratory contingency preparedness of Morocco. (under 1.6 component) 2017 Participation in REPIVET RESEPSA workshop: organized by OIE epidemiology and surveillance of animal diseases 81

84 Outcome 2: Coordination framework EuFMD participated to the REMESA JPC meeting held on th November 2015 in Algiers. During the meeting the EuFMD worlplan was endorsed A series of webinar have been planned and implementation started with the aim to improve the networking and facilitate the exchange of knowledge on FMD prevention and control within the North African countries. A preliminary meeting has been held on December 2015 with the University of Tripoli with the purpose of to discuss the possible establishment of a collaboration with the aim to: improve FMD control in Libya, development of trainings in Arabic; Support curriculum development at University of Tripoli; Outcome 3: System in place to provide improved disease risk information The activities related to this outcome are expected to be carried out from April 2016 Issues for Executive Committee attention Difficulties in Libya for RBSP and partnership with UoT (security and political instability) Difficulties in Mauritania for RBSP (commitment of Veterinary Services and pending payments). New STPs: Karima Ouali from Algeria from March to August to support the activities planned under component 2.3 and Mounir Khayli from Morocco from March to May to provide assistance to the emergency preparedness for FMD in Morocco. Priorities Maintain the collaboration and coordination with FAO and OIE in order to provide proper join assistance and support; Follow up on the targeted surveillance established in Morocco, Algeria and Tunisia; Support the development of the coordination framework REMESA networks; Establishment mutual cooperation with training providers. Support the development of vaccination self assessment tool Budget Total Budget Allowance 70,000 60,000 50,000 40,000 30,000 20,000 10, month Expenses % project completio n Actual available (9 months activities 2015) 233,218 18,052 7,7% 215,166 COMPONENT 2.3 Support to REMESA Summary of the component Programme established according to the needs and supporting the development of a regional strategy for FMD control Key elements of the programme: risk based surveillance and early warning system, self assessment on vaccination programmes, emergency preparedness, opportunities for exchanging information, improving networks and trainings Important the collaboration and coordination with FAO, OIE and REMESA countries 82

85 STC report Summary 91 st Executive Committee meeting of the EuFMD Standing Technical Committee Report.. Eoin Ryan Chair, STC Report of the STC meeting Update on STC tasks assigned at the 41 st General Session Priorities for the FAR FASTA Themes for the Open Session 2016 ExCom91 ExCom91 Report of the STC meeting in Rome, 4 th February EuFMD workplan presented and discussed Delay in obtaining DG SANTE funding risk to program delivery Benefits of partnership to program delivery Aus/NZ ExCom91 Report of the STC meeting in Rome, 4 th February Evaluation by output: complex for pillar 3 due to roles of OIE, FAO and national partners input and activity evaluation also needed for fair picture Cross cutting elements increase the impact on program delivery training, risk based surveillance, etc Alignment with EU/BTSF activities such as sharing best practice noted ExCom91 83

86 Update on Diagnostic Bank Proposal Discussed with Dr Herzog Proposal to start with bank for diagnostic reagents required in the acute phase of an outbreak testing clinical samples Advantages: Limited cost Logistically simple Addresses an ongoing gap Establishes a base from which we can build Update on Diagnostic Bank Proposal Regional focus: Balkans Ballpark capacity target: test 1,000 samples by PCR/Ag ELISA and 2,000 sera by antibody detection ELISA Laboratory network link required, coordinate with EURL/WRL and neighbouring states (Austria & Hungary) Host laboratory: reference lab in neighbourhood (IZSLER?) Post outbreak serosurveillance bank: re visit at a later stage ExCom91 ExCom91 Update on Vaccination to Live Issue Stephan Zientara to chair sub group drawn from SCRPD and STC: Kris de Clercq, Labib Bakkali Kassimi, Don King, Emi Brocchi, Eoin Ryan Objective: scope out areas of significance, report back to ExCom and Secretariat with a view towards holding a workshop Proposal: one day meeting of sub group in ANSES to work on this and report back ExCom91 Update on Contingency Planning, Business Continuity Planning and Modelling Impact of new Animal Health Law Biosecurity: need for farm and stakeholder biosecurity guidelines to facilitate them taking ownership of their own risk mitigation strategies Need for a recommended minimum biosecurity standard? Dietrich Rassow* to chair sub group drawn from SCRPD and industry to scope out issues and write a position paper on implications of Animal Health Law for contingency and business continuity planning *Resigned from STC ExCom91 84

87 FMD in Wildlife Update on Control of FMD in Wildlife Discussion of options for FMD control in wildlife Yanko Ivanov to attend simulation exercise in Bulgaria on FMD and discuss with Tsviatko Alexandrov (SCRPD) to scope out guidelines on this issue BioRisk Management Group Recent loss of Bernd Haas was noted with regret and his tremendous contribution to FMD control in Europe was praised Recommendation: commemorative event be held at Open Session Continuing work of BRMG is very important, new members needed STC recommend that Kathryn Summermatter (Switzerland) and Sebastian Allix (France) be invited to join the BRMG ExCom91 ExCom91 Fund for Applied Research STC noted that Horizon 2020 does not include any FMD funding The FAR is therefore the only FMD specific research fund at European level Priorities for the FAR were discussed by the STC Priorities for the FAR Tools to assist modelling FMD spread with respect to national data compatibility issues The practical application of the latest biosecure FMD sample transport research The application of FMD impact calculators to contingency planning The requirements for approving FMD marker vaccines within the EU Tools to manage the spread of FMD in wildlife ExCom91 ExCom91 85

88 FASTA FASTA concept Fund for applied surveillance and training awards FAST and FAST 3 training or training & technology transfer FASTA functions as a catalyst, putting partners together and leveraging existing investments to generate additional outputs STC endorsed the concept and noted its significant potential to contribute to FMD surveillance and thereby the protection of Europe The Open Session 2016 Open Session to be held in Cascais, Portugal, 25 th 28 th October Day 1: STC session (invited speakers) Days 2 and 3: Research session (non commissioned papers) Overall themes: Solutions to surveillance, biosecurity and keeping business going ExCom91 ExCom91 EuFMD #16 OS Cascais Portugal Oct 2016 EuFMD #15 OS Portugal Cidadela Cascais Historic and Art District Hotel 86

89 EuFMD #15 OS Portugal Cidadela Cascais Historic and Art District Hotel EuFMD #15 OS Portugal Cidadela Cascais Historic and Art District Hotel Cascais EuFMD #15 OS Portugal OS16 Cascais Selected hotel: lots of meeting rooms and accommodation Cheaper hotels nearby for those on limited budgets Proposal: increase registration fees by 50 (from 250/300/400 to 300/350/450 for early bird/regular/late registration) One day registration 150 euros Early bird deadline: 30 June? Deadline for abstract submission: 30 May? Deadline for poster submission: 30 June? ExCom91 87

90 Themes...? Overall: OS16 : The practice of innovation STC Day: Innovative ideas and options for FMD management Research Days: Globalising access to science and innovation: connecting livestock keepers and knowledge leaders Thank you any questions? The Standing Technical Committee: Stephan Zientara Yanko Ivanov Dietrich Rassow [resigned] Eoin Ryan Thanks to Keith, Jenny, Marius, Nadia and the team ExCom91 ExCom91 Contract with WRL Pirbright Previous contract finished 31 October 2015 Final report delivered, final payment made Draft LOA prepared in line with components 1.7 and To be discussed with WRL ExCom91 88

91 FAO and OIE FAO and OIE Assistance to EuFMD in PILLARS II and III Contents FAO supports to its membership this past year Global FMD Control Strategy where we are! Third roadmap meeting for Middle East countries Regional Leading Laboratories for virus pools 3 5 FMD WG: priorities and plan for 2016 OIE activities relevant to FMD at the Global level FMD activities in North Africa FAO FMD Pillars I and III FAO FMD Pillars III GS 3 TCP TF TCP/DRK/3405 (NTE: ) - Emergency assistance for responding to foot-and-mouth disease (FMD) $ 435,000 outbreaks and strengthening control capacity DPRK TCP/PAK/3503 (NTE: ) - Development of National Control Program for Foot and Mouth Disease in $ 448,000 Pakistan TCP/SRL/3503 BABY01 (NTE: ) - Technical Assistance to improve Foot and Mouth Disease $ 31,753 (FMD) vaccine production in Sri Lanka TCP/UGA/3503 (NTE: ) Uganda - Emergency measures for outbreak containment and risk-based $ 500,000 strategic control of foot-and-mouth disease TCP/ZIM/3503 (NTE: ) Zimbabwe - Emergency support for the control of foot-and-mouth $ 500,000 disease (FMD) MTF /INT/003/EEC (NTE: ) - EC Funded Activities ( ) carried out by the FAO European $ 9,425,861 Commission for the Control of Foot-and-Mouth Disease (EUFMD) - (Follow up Phase MTF /INT/003/EEC) MTF /INT/011/MUL (NTE: ) - European Commission for Control of Foot-And-Mouth Disease $ 11,436,762 OSRO/AFG/402/JPN (NTE: ) - Building resilience and self-reliance of livestock keepers by improving control of Foot-and-Mouth Disease (FMD) and other Transboundary Animal Diseases (TADs) $ 16,754,787 Afghanistan TCP/GHA/3401 (NTE: ) - Support in reviewing animal health and production Legislation in Ghana $ 62,156 TCP/INS/3402 (NTE: ) - Development of preventive aquatic animal health protection plan and $ 422,000 enhancing emergency response capacities to shrimp disease outbreaks in Indonesia TCP/RER/3402 (NTE: ) - Assistance to Western Balkan Countries for Improving Compliance with $ 377,000 International Standards for Aquatic Animal Health TCP/SUR/3401 (NTE: ) - Strengthening Aquatic Animal Health Protection Systems in Suriname $ 400,000 TCP/SWA/3301 (NTE: ) - Development and operation of an enhanced livestock identification and $ 331,000 traceability scheme integrated within an animal health information system TCP/TAJ/3501 (NTE: ) - Formulation of a project for Strengthening Capacity of MoA in Policy $ 67,500 Formulation and Animal Health Services TF OSRO/GLO/102/AUL (NTE: ) - Partnership on global animal health and biosecurity initiatives $ 2,054,207 OSRO/GLO/102/AUL(NTE: ) - Crisis Management Centre-Animal Health (CMC-AH) $ 528,459 OSRO/GLO/102/AUL (NTE: ) - Partnership on global animal health $ 167,014 GCP /RAS/283/ROK (NTE: ) - "Foot-and-Mouth Disease Control in Southeast Asia through TF/GCP Application of the Progressive Control Pathway", within the framework of "Improving National Preparedness $ 2,800,908 for Transboundary Animal Infectious Disease in Developing Countries in Southeast Asia" MTF /INT/003/EEC (NTE: ) - EU Funded Activities ( ) carried out by the FAO European $ 4,670,226 Commission for the Control of Foot-and-Mouth Disease (EUFMD) MTF /INT/004/MUL (NTE: ) - Foot and Mouth Disease - Emergency Aid Programme $ 1,910,882 UTF /IRA/063/IRA (NTE: ) - Purchase of gas tight doors for the Foot and Mouth Disease TF/UTF $ 801,470 Surveillance Centre, Golmakan, Khorasan Razavi Province, Iran. OSRO/INT/901/NET (NTE: ) - Support to the FAO Animal Health Service in infectious and vector borne $ 1,215,002 disease control and to FAO Indonesia in the prevention and control of HPAI OSRO/INT/902/USA (NTE: ) - Support for Strengthening Animal Health Laboratory Capacities in Hot $ 21,794,371 Spot Regions to Combat Zoonotic Diseases that Pose a Significant Public Health Threat - OSRO/SRB/404/BEL (NTE: ) - Emergency animal health support for small scale livestock holders $ 100,000 affected by the floods in Serbia OSRO/SYR/309/USA (NTE: ) - Emergency Assistance to Strengthen Veterinary Services and Mitigate $ 500,000 the Deterioration of the Animal Health Situation in Syria. TF/ GCP /ETH/083/EC (NTE: ) - Pursuing Pastoral Resilience (PPR) through improved animal health service GCP $ 11,787,729 delivery in pastoral areas of Ethiopia 89

92 FAO FMD GS Component 2 and 3 OSRO/BGD/303/USA (NTE: ) - Strengthening National Capacity to Respond to Emerging and $ 1,750,000 Re-Emerging Pandemic Threats Including Highly Pathogenic Avian Influenza (HPAI) in Bangladesh OSRO/BGD/403/USA (NTE: ) - Strengthening National Capacity to Prevent and Control $ 1,500,000 Emerging and Re-Emerging Pandemic Threats Including Influenza A in Bangladesh OSRO/EGY/501/USA (NTE: ) - Strengthening national capacity for preparedness early $ 2,900,000 detection and response to emerging pandemic threats (EPT-2) OSRO/INS/501/USA (NTE: ) - Strengthening National Capacity to Prevent and Control $ 4,000,000 Emerging and Re-Emerging Pandemic Threats Including Influenza A in Indonesia (EPT-2) OSRO/INT/001/USA (NTE: ) - FAO EPT+ Proposal: Characterizing Influenza Viruses Posing $ 4,550,000 Risks as the Next Global Pandemic TCP/JOR/3502 (NTE: ) - Enhanced Surveillance of Transboundary Animal Diseases in rural $ 450,000 areas of Jordan affected by the crises in Syria. TF OSRO/AFG/402/JPN (NTE: ) - Building resilience and self-reliance of livestock keepers by $ 16,754,787 improving control of Foot-and-Mouth Disease (FMD) and other Transboundary Animal Diseases (TADs) OSRO/GLO/502/JPN (NTE: ) - Strengthening International Responses to Transboundary Animal $ 2,491,960 Diseases TADs GCP /GLO/340/ITA (NTE: ) - Global Framework for the Progressive Control of Transboundary $ 887,519 Animal Diseases GCP /GLO/340/ITA BABY01 (NTE: ) - Support to Global Framework for Progressive Control of $ 13,625 Transboundary Animal Diseases - Baby 1 GCP /GLO/442/USA (NTE: ) - Animal-Human Interface Liaison Establishment of ongoing $ 325,000 collaboration between US CDC and FAO for surveillance, prevention and control of major transboundary animal diseases including key zoonoses. GCP /GLO/487/EC (NTE: ) - Linking Epidemiology and Laboratory Research on $ 247,405 Transboundary Animal Diseases and zoonoses in China and EU -LinKTads FAO Projects on TADs and Other Livestock Emergencies in RNE FAO implemented projects in 15 countries (US$ 50 million; mostly donor-funded projects) Productivity improvement TADs and risk analysis Zoonosis Dairy and poultry Sheep and goats GCP /RAS/279/JPN (NTE: ) - Information Sharing for Transboundary Animal Diseases (TADs) in Asia $ 228,1 6 Also FAO support provided: present Angola: FAO/OIE Crisis Management Centre Animal Health Nov Dec 2015 Assessment of FMD outbreaks and factors contributing to its spread Underlying constrains for the implementation of surveillance and related mitigations Vaccination strategy and laboratory capacity Technology transfer: ~24 countries Molecular technologies and equipment (FAO and FAO/IAEA) Lab and Epidemiology Networks RESEPI, RESOLAB, EARLN, ASEAN Field Epidemiology Training for Veterinarians Good Emergency Management Practices (East Europe, CIS) FMD Global Strategy Global, National and Regional Approach Global National Regional FAO OIE FMD WG Developed the GS and coordinate it s implementation Global Network: OIE/FAO FMD Reference Lab Network Epidemiology network Use of PCP FMD guidelines as tool for implementation Countries investment and control plans (FAO, OIE and donor support) Performance of veterinary services (PVS) Training and Seminars Regional control strategy Regional roadmap meetings for country assessment Regional laboratory and epidemiology networks 8 90

93 Regional Roadmap Meetings Convened Since 2012 Feedback to Country (example) PHEFA SEAC FMD validated stages provisional stages (not validated) Tajikistan Pools Roadmap meetings 9 First roadmap in countries 3 rd FMD Roadmap for the Middle East December 2015 Number of Countries per PCP stage Virus Pools 2 4 Country Bahrain * Egypt 1 1 2* 2* Iraq 2 2 2* 2* Jordan 1 1 2* 2* Palestine 1 1 Kuwait * Lebanon 1 1 2* 2* Oman 2 2 2* 2* Qatar 2 2 3* SaudiArabia 1 1 2* 2* Syria 2 2 2* 2* UAE Yemen 1 1 1* 1* % % 58% 33% 17% Between 2012 and 2015, countries advanced in PCP stages with clear shift to have more countries in PCP stages 1 and 2 in 2015 compared to A few countries progressively advanced to stages 3 and 4. stage 0 Stage1 Stage 2 Stage 3 91

94 FMD GOBAL STRATEGY Progress Global FMD control is feasible and can be a driver to improve animal health systems, trade, nutrition and economic growth PCP FMD approach and reinforcement of veterinary systems are gradually gaining acceptance. Sixty countries are engaged and 42 countries are closely monitored with notable evidence of advancement Political will and engagement of international and regional organizations and development partners are crucial to the startup and sustainability of FMD control Funding is needed to support the global strategy, particularly those countries at lower PCP stages Vaccination issues need to be addressed by the government authority and research community Roadmap meetings are being attended by third parties ( potential investors?), especially in West Eurasia and East Africa. Some (Major) Challenges Areas Diagnostics: capabilities to carry out sustainable surveillance Field investigations and collection and shipping of samples Lab biosafety and biosecurity Equipment and reliable flow of diagnostic supplies Vaccine: Low vaccine coverage and resources to buy vaccine Vaccination regimens for small ruminants Effective vaccination programs risk based Good quality vaccine; appropriate payload Reporting and early warning: Lack of early warning system and real time disease reporting Poor capture and reporting at village level Regional action plans: FMD control for hot spots (ecosystems for virus emergence; re emergence) Concerted regional control plan (i.e., PHEFA, SEACFMD; political will) Animal movement management / understanding value chains Endorsement of public private partnership Routine surveillance and sero monitoring Competing priorities Priorities GF TADs FMD Working Group with EuFMD Train OIE and FAO field staff, RAG & global expert group on PCP Identify training needs and conduct roadmap meetings Prepare 5 year plan for the implementation of the global strategy (WG only) Publish PVM and finalize the socioeconomic guidelines Produce 2 nd edition the PCP FMD guidelines and its questionnaires Develop guiding material for FMD control plans 92

95 PCP Training for FAO and OIE staff To improve the awareness, and increase the appropriate application of the PCP FMD tool; To clarify the link between the PCP FMD and PVS tools under the component 2 of the Global Strategy; To clarify the relation between the PCP FMD tool and the OIE procedure for endorsement of official control programme for FMD and for recognition of FMD free status. Ultimate goal: All regional / sub regional officers should be able to provide guidance to countries and to better follow up their respective regional roadmap ( and apply such risk management approaches to other threats of animal origin). PCP FMD guidelines 2 nd Edition & associated questionnaires To build on the experiences gained when implementing the PCP FMD To include Component 2 of the FMD Global Strategy Strengthening Veterinary Services TBC (GF TADs Management Commitee) Guiding material for FMD Control Plans required Template for control plans to support countries willing to progress to PCP Stages 1, 2 and 3 and to advance in their PCP stage. Post vaccination monitoring (PVM) guidelines to be published Socio economic guidelines, to guide countries to: Estimate the impact of FMD; Determine the cost benefit for country and donor investments; Obtain economic data to design better FMD control policies. Technical document to be included in the guidelines toolkit of the FAO/OIE FMD Global Strategy Regional Leading Laboratories Need OIE-FAO FMD Reference Laboratory Network FMD Seven Regional Virus Pools WRL- FMD Reference lab/centers 93

96 Regional Leading Laboratory (RLL) Recognised and nominated by the region Support of the Working Group to the process Draft of the criteria Development of the evaluation/nomination process Benefit for the region Access to training Access to diagnostic reagent, proficiency testing Benefit for the RLL Financial support from donors Technical support, possible candidate for twinning project, potential Reference Laboratory / Centre OIE FMD OIE activities relevant to FMD at the global level International Standards revision of the Code and Manual Official status recognition freedom with or without vaccination Endorsement of official control programme OIE Reference Centres Twinning Vaccine banks PVS (Component 2 of the Global Strategy) International Standards 94

97 FMD in North Africa in 2014/2015 FMD activities in North Africa The strain (O/ME SA/Ind 2001 serotype O) circulated in 2014 in Tunisia and Algeria was introduced into Libya in 2013 new serotype in the Maghreb Region coming from Middle East This FMD strain was detected in Morocco in October The sequencing of this new strain showed that it is distant in the phylogenetic tree from the strain (also serotype O) circulated in Libya in the recent past OIE Sub Regional Representation for North Africa Tunis, Tunisia ( ) SAT 2 was notified by Mauritania in The last notification of FMD in Mauritania was in 2006 FMD in North Africa in 2014/2015 Lesson learnt from the 2014/2015 FMD epidemic Potential pathway of the introduction of FMD strain O/ME SA/Ind 2001 in Libya in 2013 from the Indian Continent based on the epidemiological investigation carried out by the Libyan Veterinary Authority and subsequent spreading to Tunisia, Algeria and Morocco Difficulties were encountered in controlling animal movements between the countries and within the countries; No financial compensation mechanisms available in Tunisia to implement the stamping out; Difficulties were faced when dealing with animal traders; Difficulties in having immediate availability of appropriate vaccine for some countries that were ready to pay for it (e.g. Algeria and Morocco); Difficulties in implementing regular active surveillance in the affected countries; Challenges related to the political instability in some countries in the region such as Libya 95

98 Endorsement by the OIE of an official control programme for FMD REMESA Joint Secretariat (OIE-FAO) In May 2012: Tunisia, Algeria and Morocco were recognised by the OIE as Member Countries with endorsed official control programme for FMD REseau MEditerranéen de Santé Animale (REMESA) (Mediterranean Animal Health Network) Following the FMD epidemic the OIE withdrawed the endorsement of FMD official control programme of Tunisia in September 2014 and Algeria in February 2016 Greece Malta Cyprus Jordan Lebanon OIE FMD Vaccine bank OIE FMD Vaccine bank NOVEMBER 2014 At the 9th meeting of the JPC held in Tunis, the OIE was entrusted by REMESA Countries to implement a regional bank for North Africa of vaccines and antigens for FMD to allow access to high quality vaccines or antigens for the countries of the Region complying with intergovernmental standards in particular in emergency situation through an international call for tender prepared by the OIE This project is in progress... 96

99 JPC REMESA (ALGERIA) OIE SSR Tunis working plan for 2016 Reiterated the importance of establishing a regional vaccine bank for FMD in the REMESA region but, in parallel: Vaccine bank would be beneficial only if there is a harmonized vaccination strategy among the countries; Crucial to have an effective livestock animal identification (traceability of the animal movements) In 2016 the OIE Office in Tunis is planning to organise at least: 1 Workshop dedicated to elaborate an harmonised vaccination strategy in the North African Region 1 Workshop dedicated to discuss livestock identification system including small ruminants Workshop dedicated to elaborate an harmonised vaccination Workshop dedicated to elaborate an harmonised vaccination Workshop dedicated to elaborate an harmonised vaccination strategy in the North African Region The invited experts from FMD Reference Laboratory: Pirbright (UK) 1 expert Brescia (Italy) 1 expert ANSES (France) 1 expert With the support of 1 expert from EuFMD The final goal of the workshop is to elaborate and to be agreed on a harmonised and feasible vaccination strategy for FMD to be presented at the next REMESA meeting The major elements to be discussed and agreed during the workshop are as follows: Which species need to be vaccinated and at what ages; Which serotypes need to be used; Timing of vaccination programme; Agreement on the availability of having the sufficient logistic elements to carry out the vaccination campaign (e.g. adequate "cold chains", accessibility of target livestock populations to vaccination, well trained vaccination teams); Possibility of taking advantage of the vaccination campaigns to identify the animals; Which key elements of the surveillance systems to monitor effectiveness of vaccination should be available and used in the countries; Which type of surveillance systems is needed to monitor the prevalence of the disease in both bovine and small ruminants; risk based active and passive surveillance; Economic impact of the vaccination campaigns (human resources, budget, cost/benefits issues, stamping out.) 97